Method for preparing polyethylene glycol-modified uricase
By performing PEG covalent modification on uricase at specific sites, the problems of high immunogenicity and allergic reactions of uricase in the human body were solved, resulting in a highly stable and low immunogenic uricase suitable for intramuscular injection, thus improving the efficacy of treating hyperuricemia and gout.
Patent Information
- Application Number
- CN202011224610.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2020-11-05
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2040-11-05
AI Technical Summary
Existing uricases have high immunogenicity and allergic reactions when used in humans, making them unsuitable for long-term treatment of hyperuricemia and gout. Furthermore, existing PEG-modified uricases such as Pegloticase have limitations in terms of molecular weight and administration methods.
By covalently modifying uricase at specific sites with polyethylene glycol (PEG), and providing PEG in an acidic solution, the modification sites and reaction conditions can be controlled to ensure that enzyme activity is not reduced, immunogenicity is decreased, and the enzyme is suitable for intramuscular injection.
It achieves high stability and low immunogenicity of uricase in the human body, and the efficacy after intramuscular injection is comparable to that after intravenous injection, reducing the risk of antibody production and improving treatment compliance.
Smart Images

Figure BDA0002763226740000181 
Figure BDA0002763226740000182 
Figure BDA0002763226740000191
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedicine, and specifically, the present invention relates to a method for preparing polyethylene glycol-modified uricase, and more specifically, the present invention relates to a method for preparing polyethylene glycol-modified uricase, a method for reducing the immunogenicity of uricase, polyethylene glycol-modified uricase, a drug combination, and pharmaceutical use of polyethylene glycol-modified uricase. Background Art
[0002] Gout is a disease caused by purine metabolism disorder. Its clinical characteristics are hyperuricemia and the formation of tophi due to the deposition of urate in the subcutaneous tissue, joints and kidneys. Purine in the human body undergoes a series of changes, and the final product is uric acid. When the blood uric acid concentration exceeds 70mg / L, it can cause hyperuricemia. Among them, 5% to 12% of patients with hyperuricemia may develop gout. In the blood or synovial fluid, when the concentration of sodium urate reaches saturation, microcrystals of sodium urate salt can be formed, leading to gouty arthritis. Over time, chronic hyperuricemia can also deposit destructive crystalline uric acid deposits around joints, in soft tissues and in certain organs, which can lead to diseases such as acute gouty arthritis, chronic tophi arthritis and joint deformities. Kidney damage is considered to be the second most common clinical manifestation of gout. Chronic hyperuricemia progressively leads to the deposition of urate in the medulla, renal tubules and renal interstitium, which stimulates local area and causes inflammatory reaction, which is called chronic urate nephropathy. In patients with severe hyperuricemia (such as certain malignant tumors, especially leukemia and lymphoma patients), a large amount of uric acid may be deposited in the renal collecting ducts, renal pelvis, renal calyces and ureters in a short period of time, causing tubular obstruction, urinary retention and acute renal failure (also known as uric acid nephropathy).
[0003] In recent decades, with the improvement of people's quality of life and changes in diet and living habits, the intake of high-protein and high-purine foods has increased, and the number of gout patients has been increasing year by year. In Europe, the number of gout patients has doubled in the past 20 years. The current incidence of hyperuricemia and gout in my country has increased to about 2-3%. If hyperuricemia does not show clinical symptoms, diet control is sufficient; when clinical symptoms caused by it appear, drug treatment is required. Conventional treatments currently used in clinical practice include: analgesic and anti-inflammatory drugs, such as colchicine, buprofen, naproxen, etc., which are mainly used to control the acute symptoms of gouty arthritis and eliminate local joint pain, swelling and inflammation; uricosuric agents that promote uric acid excretion (ineffective if renal function is reduced), such as probenicid, sulfinpyrazone, benzbromarone, etc.; drugs that inhibit uric acid synthesis, such as allopurinol. For patients with tophaceous gout, renal insufficiency, leukemia and certain genetic diseases, allopurinol is the main treatment drug. It can inhibit xanthine oxidase, so that hypoxanthine and xanthine cannot be converted into uric acid. It itself is gradually oxidized in the human body to form water-soluble isoxanthine (oxipurinol) and excreted through urine. However, all conventional therapies are difficult to cure patients with chronic gout who have formed tophi. In addition, after taking the above drugs for a long time, patients will inevitably experience the following complications: leukopenia, impaired heart function, impaired liver and kidney function, irritation of the gastrointestinal system, aplastic anemia leading to diabetes, gout, and other complications.
[0004] Human hyperuricemia is related to the inactivation of the uricase gene mutation during human evolution. The mutation introduces a premature stop codon in the coding sequence of the human uricase gene (Wu X, Lee CC, Muzny DM, Caskey CT. Proc Natl Acad Sci USA. 1989. 86: 9412-9416.). As a result, humans cannot synthesize active uricase by themselves, causing human purine catabolism to terminate at uric acid (Wu X, Muzny DM, Lee CC, Caskey CTJ Mol Evol. 1992. 34: 78-84.). Active uricase in the liver peroxisomes of non-human primates and other mammals can convert the less soluble urate (~11 mg / 100 ml water) into the more soluble allantoin (~147 mg / 100 ml water), which can be excreted more efficiently by the kidneys (Wortmann RL, Kelley W N. Kelley's textbook of rheumatology (6th). 2001: 1339-1376). In Europe and the United States, uricase prepared from Aspergillus flavus has been used for more than 10 years in the treatment of severe hyperuricemia associated with tumor chemotherapy (Zittoun R, Dauchy F, Teilaud C, Barthelemy M, Bouchard P. Ann Med Interne. 1978. 127: 479-482.). ELITEK, a recombinant aflatoxin uricase drug produced by brewer's yeast fermentation and developed by Sanofi in France, has been approved by FDA in 2002 and used for short-term treatment of severe hyperuricemia caused by tumor chemotherapy (Pui CH, Relling MV, Lascombes F, Harrison PL, Struxiano A et al. Leukemia. 1997. 11: 1813-1816.). At the same time, it has been proven that the infusion of ELITEK can also reduce the volume of tophi (Potaux L, Aparicio M, Maurel C, Ruedas ME, Martin CL. Nouv Presse Med. 1975. 4: 1109-1112.). Pegloticase, a recombinant porcine uricase produced by Savient in the United States and approved by FDA for marketing in September 2010, is used to treat refractory gout. However, since it does not solve the problem of immunogenicity, it is ineffective in about 50% of patients in clinical applications.
[0005] Uricase (EC 1.7.3.3) is widely present in microorganisms (Bacillus fastidious, Candida albicans, Aspergillus flavus), plants (soybeans, chickpeas), and animals (pigs, cattle, dogs, baboons) (Suzuki K, Sakasegawa S, Misaki H, Sugiyama M. J Biosci Bioeng. 2004. 98: 153-158). In the presence of oxygen, it can catalyze the oxidation of uric acid to allantoin and release carbon dioxide (Retailleau P, Colloc'h, Denis V, Francoise B. Acta Cryst D. 2004. 60: 453-462.).
[0006] Active uricase is a tetrameric protein composed of identical subunits, each of which has a molecular weight of about 34 kD and is composed of 301-304 amino acids. The highest pH value of uricase activity in each solution is 8.0 (Bayol A et al. Biophys Chem. 1995. 54: 229-235.). Among all the known sources of uricase, the most active one comes from Aspergillus flavus, reaching 27 IU / mg; the second most active one comes from Bacillus fastidious, with an activity of 13 IU / mg (Huang SH, Wu TT. Eur J Biochem. 2004. 271: 517-523.). In addition, the activity of uricase from legumes is only 2 to 6 IU / mg. After recombinant expression, the activity of uricase from mammals can reach 5 IU / mg in pigs, and the activity of uricase from baboons is only 1 IU / mg (Michael H, Susan J.K. 2006. US7056713B1), while human uricase is inactive.
[0007] As for human application, the high activity of microbial uricase and the low immunogenicity of mammalian uricase make these two sources of uricase the research hotspots of recombinant uricase currently being developed and applied. However, the homology between the uricase from Aspergillus flavus and the inferred human uricase is less than 40% (Lee CC, Wu X, Gibbs RA, Cook RG, Muzny DM, Caskey CT. Science. 1988. 239: 1288-1291.), and the human body is prone to produce anti-uricase antibodies. The efficacy of Aspergillus flavus uricase is rapidly weakened, and severe allergic reactions are induced, making it unusable for long-term treatment. The human uricase gene mutates and loses its activity, becoming a pseudogene.
[0008] Therefore, urate oxidase-based technology for treating hyperuricemia still needs further development and improvement. Summary of the invention
[0009] This application is based on the inventor's discovery and understanding of the following facts and problems:
[0010] Active uricase is a homotetrameric protein, one-third of which are highly hydrophobic amino acids. Tetrameric proteins easily aggregate to form octamers and larger aggregates. Molecules with a molecular weight of more than 100 kDa can effectively induce an immune response in the body, and the molecular weight of unmodified polymeric uricase protein has reached 140 kDa. Polymeric uricases with larger molecular weights will have higher immunogenicity. The human body is prone to produce anti-uricase antibodies, which rapidly weaken its efficacy and induce severe allergic reactions, making it unsuitable for long-term treatment. Covalent modification of proteins with PEG has been shown to reduce protein immunogenicity, increase protein solubility, and prolong the half-life of proteins.
[0011] Duke University and Savient conducted a study on chimeric uricases from pigs and baboons (Michael H, Susan JK2006.US7056713B1). The method of this study is to modify the ε-amino group of the lysine residues of the pig-like uricase by a polyethylene glycol (10KDa-mPEG-NPC) with a molecular weight of 10KDa containing methoxy groups (the modified product obtained is Pegloticase), while ensuring that the enzyme activity is not significantly reduced, and preliminarily achieve the goal of being used in the human body to treat intractable gout. The inventor found that the above research results cannot completely solve the immunogenicity problem caused by the drug. After multiple injections of clinical subjects, the phenomenon of disappearance of the efficacy of uricase appeared. The inventor speculated that this may be related to the excessive molecular weight of Pegloticase protein (Pegloticase molecular weight is 540kDa). At the same time, because pegloticase is not suitable for injection, it is suitable for intravenous injection, which reduces the compliance of the subjects for long-term use, thereby seriously limiting its clinical application. To date, there is no long-acting uricase drug that is less immunogenic and can be injected subcutaneously.
[0012] The present invention aims to solve one of the technical problems in the related art at least to a certain extent.
[0013] In a first aspect of the present invention, a method for preparing polyethylene glycol-modified uricase is provided. According to an embodiment of the present invention, at least 11 of the following amino acid sites of the polyethylene glycol-modified uricase are PEG-modified, T 1 , K 3 , K 4 , K 30 , K 35 , K 76 , K 79 , K97 , K 112 , K 116 , K 120 , K 152 , K 179 , K 222 , K 231 , K 266 , K 272 , K 285 , K 291 , K 293 The method comprises: coupling uricase and polyethylene glycol, wherein the polyethylene glycol is provided in the form of an acidic solution, and the molar ratio of the uricase to the polyethylene glycol is 1:(56-94), so as to obtain polyethylene glycol-modified uricase. The polyethylene glycol-modified uricase prepared by the method of the embodiment of the present invention has a modification site T 1 , K 3 , K 4 , K 30 , K 35 , K 76 , K 79 , K 97 , K 112 , K 116 , K 120 , K 152 , K 179 , K 222 , K 231 , K 266 , K 272 , K 285 , K 291 , K 293 At least 11 sites in the preparation are PEG-modified. It should be noted that the "uricase" prepared in the present application should be understood in a broad sense, which refers to the general term for the mixture of uricases produced in the same batch in actual production practice. The polyethylene glycol-modified uricase obtained by the method according to the embodiment of the present invention can greatly improve the in vivo stability of uricase and reduce immunogenicity while ensuring the enzyme activity to the maximum extent, and the in vivo efficacy after intramuscular injection can achieve the equivalent in vivo efficacy of the original drug after intravenous injection.
[0014] According to an embodiment of the present invention, the above method may further include at least one of the following additional technical features:
[0015] According to an embodiment of the present invention, the polyethylene glycol is provided in the form of an acidic solution. The inventors have found that by dissolving PEG in an acidic solution, the activation group hydrolysis of the polyethylene glycol before reacting with the protein can be prevented, thereby effectively ensuring the effective activation efficiency of the polyethylene glycol, and at the same time solving the defects of excessive local concentration, uneven dissolution, uneven contact between the polyethylene glycol and the coupling protein, and generation of bubbles to interfere with the coupling reaction when the polyethylene glycol solid is directly dissolved in the coupling reaction buffer, thereby effectively improving the coupling reaction efficiency of urate oxidase and polyethylene glycol.
[0016] According to an embodiment of the present invention, the acidic solution is an acidic solution containing at least one selected from organic acid and inorganic acid.
[0017] According to an embodiment of the present invention, the organic acid is selected from:
[0018] Acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid, malonic acid, adipic acid, ascorbic acid, benzenesulfonic acid, benzoic acid, butyric acid, cyclopentylpropionic acid, digluconic acid, dodecylsulfuric acid, ethanesulfonic acid, formic acid, fumaric acid, glucoheptonic acid, glycerophosphoric acid, gluconic acid, heptanoic acid, hexanoic acid, 2-hydroxy-ethanesulfonic acid, lactobionic acid, lactic acid, lauric acid, laurylsulfuric acid, malic acid, malonic acid, methanesulfonic acid, 2-naphthalenesulfonic acid, nicotinic acid, oleic acid, palmitic acid, pectic acid, 3-phenylpropionate, picrate, pivalic acid, propionic acid, stearic acid, p-toluenesulfonic acid, undecanoic acid, valeric acid;
[0019] According to an embodiment of the present invention, the inorganic acid is selected from:
[0020] Hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, perchloric acid, hydroiodic acid, nitric acid, persulfuric acid, boric acid, dichromic acid, silicic acid, chromic acid, thiocyanic acid.
[0021] According to an embodiment of the present invention, the concentration of hydrogen ions in the acidic solution is 1-5 mmol / L.
[0022] According to an embodiment of the present invention, the acidic solution contains hydrochloric acid or sulfuric acid or glacial acetic acid.
[0023] According to an embodiment of the present invention, the concentration of the acid in the acidic solution is 1-5 mmol / L.
[0024] According to an embodiment of the present invention, the molar ratio of uricase to polyethylene glycol is 1:(45-110).
[0025] Preferably, the molar ratio of uricase to polyethylene glycol is 1:(56-94).
[0026] According to an embodiment of the present invention, the concentration of the polyethylene glycol in the acid solution is 100-300 mmol / L. The inventors found that when the concentration of the polyethylene glycol in the acid is within the above concentration range, the viscosity of the reaction solution is appropriate, which is conducive to improving the reaction efficiency and expanding industrial production.
[0027] According to an embodiment of the present invention, the molecular weight of the polyethylene glycol is no more than 6KD. The inventors have found that by using polyethylene glycol with a molecular weight of no more than 6KD to carry out coupling reaction with uricase, the long-term effect of the polyethylene glycol-modified uricase oxidase obtained in vivo is further enhanced, and no anti-uricase antibodies are generated, and almost no anti-PEG antibodies are generated, that is, the immunogenicity is further reduced.
[0028] According to an embodiment of the present invention, the polyethylene glycol has a monomethoxy group or a hydroxyl group.
[0029] According to an embodiment of the present invention, the polyethylene glycol is a linear or branched structure.
[0030] According to an embodiment of the present invention, the polyethylene glycol is coupled to uricase via an amide bond.
[0031] According to an embodiment of the present invention, the polyethylene glycol is a modified polyethylene glycol, and the modification group of the modified polyethylene glycol is selected from:
[0032] N-hydroxysuccinimide, N-hydroxysuccinimide carbonate, N-hydroxysuccinimide acetate, N-hydroxysuccinimide propionate, N-hydroxysuccinimide butyrate, N-hydroxysuccinimide succinate and p-nitrophenyl carbonate.
[0033] According to an embodiment of the present invention, the modified group of the modified polyethylene glycol is N-hydroxysuccinimide.
[0034] According to an embodiment of the present invention, the coupling reaction is carried out in a carbonate buffer solution.
[0035] According to an embodiment of the present invention, the pH of the carbonate buffer solution is 9 to 11. The inventors found that when the buffer pH is below 9.0, the solubility of uricase will be seriously affected, and the next modification reaction cannot be performed. When the buffer pH is higher than 11, the activity of uricase will be seriously affected, and the coupling efficiency of polyethylene glycol and uricase oxidase will also be reduced.
[0036] According to an embodiment of the present invention, the concentration of the uricase oxidase in the coupled reaction system is 10 mg / ml. The inventors found that the concentration of the uricase oxidase in the coupled reaction system is within the above concentration, and the viscosity of the reaction solution is appropriate, which is conducive to improving the reaction efficiency and expanding industrial production. At the same time, the inventors found that the protein concentration of the uricase oxidase affects the average modification degree of the uricase oxidase. When the obtained uricase oxidase has the same average modification degree of PEG, the urate oxidase of 10 mg / ml requires a low PEG feed ratio, saving production costs.
[0037] According to an embodiment of the present invention, the coupling reaction is carried out at a temperature of 5 to 30° C. for at least 60 minutes. The coupling reaction is carried out at the above temperature for at least 60 minutes, which can effectively achieve the T 1 , K 3 , K 4 , K 30 , K 35 , K 76 , K 79 , K 97 , K 112 , K 116 , K 120 , K 152 , K 179 , K 222 , K 231 , K 266 , K 272 , K 285 , K 291 , K 293 At least 11 sites in the peptide were PEGylated.
[0038] According to an embodiment of the present invention, the coupling reaction product is further subjected to ultrafiltration and / or purification treatment, thereby effectively removing unmodified polyethylene glycol and byproducts, such as NHS, and effectively improving the purity of the obtained polyethylene glycol-modified uricase.
[0039] According to an embodiment of the present invention, at least one of the following four amino acid sites has PEG modification, K 30 , K 35 , K 222 and K 231 .
[0040] According to an embodiment of the present invention, the amino acid site positioning is based on the amino acid sequence shown in SEQ ID NO:1.
[0041] TYKKNDEVEFVRTGYGKDMIKVLHIQRDGKYHSIKEVATTVQLTLSSKKDYLHGDNSDVIPTDTIKNTVNVLAKFKGIKSIETFAVTICEHFLSSFKHVIRAQVYVEEVPWKRFEKNGVKHVHAFIYTPTGTHFCEVEQIRNGPPVIHSGIKDLKVLKTTQSGFEGFIKDQFTTLPEVKDRCFATQVYCKWRYHQGRDVDFEATWDTVRSIVLQKFAGPYDKGEYSPSVQKTLYDIQVLTLGQVPEIEDMEISLPNIHYLNIDMSKMGLINKEEVLLPLDNPYGKITGTVKRKLSSRL(SEQ ID NO:1).
[0042] According to an embodiment of the present invention, the urate oxidase has the amino acid sequences shown in SEQ ID NO: 1-7.
[0043] MAHYRNDYKKNDEVEFVRTGYGKDMIKVLHIQRDGKYHSIKEVATSVQLTLSSKKDYLHGDNSDVIPTDTIKNTVNVLAKFKGIKSIETFAVTICEHFLSSFKHVIRAQVYVEEVPWKRFEKNGVKHVHAFIYTPTGTHFCEVEQIRNGPPVIHSGIKDLKVLKTTQSGFEGFIKDQFTTLPEVKDRCFATQVYCKWRYHQGRDVDFEATWDTVRSIVLQKFAGPYDKGEYSPSVQKTLYDIQVLTLGQVPEIEDMEISLPNIHYLNIDMSKMGLINKEEVLLPLDNPYGRITGTVKRKLTSRL(SEQ ID NO:2).
[0044] MYKNDEVEFVRTGYGKDMVKVLHIQRDGKYHSIKEVATSVQLTLSSKKDYVYGDNSDIIPTDTIKNTVHVLAKFKGIKSIETFAMNICEHFLSSFNHVIRAQVYVEEVPWKRFEKNGVKHVHAFIHNPTGTHFCEVEQMRSGPPVIHSGIKDLKVLKTTQSGFEGFIKDQFTTLPEVKDRCFATKVYCKWRYHQGRDVDFEATWDTVRDIVLEKFAGPYDKGEYSPSVQKTLYDIQVHSLSRVPEMEDMEISLPNIHYFNIDMSKMGLINKEEVLLPLDNPYGKITGTVKRKLSSRL(SEQ ID NO:3)。
[0045] MAHYHNDYKKNDEVEFVRTGYGKDMVKVLHIQRDGKYHSIKEVATSVQLTLSSKKDYVYGDNSDIIPTDTIKNTVHVLAKFKGIKSIETFAMNICEHFLSSFNHVIRAQVYVEEVPWKRFEKNGVKHVHAFIHNPTGTHFCEVEQMRSGPPVIHSGIKDLKVLKTTQSGFEGFIKDQFTTLPEVKDRCFATKVYCKWRYHQGRDVDFEATWDTVRDIVLEKFAGPYDKGEYSPSVQKTLYDIQVHSLSRVPEMEDMEISLPNIHYFNIDMSKMGLINKEEVLLPLDNPYGRITGTAKRKLASKL(SEQ ID NO:4)。
[0046] MAHYHNDYQKNDEVEFVRTGYGKDMVKVLHIQRDGKYHSIKEVATSVQLTLNSRREYLHGDNSDIIPTDTIKNTVQVLAKFKGIKSIETFAMNICEHFLSSFNHVIRVQVYVEEVPWKRFEKNGVKHVHAFIHTPTGTHFCEVEQLRSGPPVIHSGIKDLKVLKTTQSGFEGFLKDQFTTLPEVKDRCFATQVYCKWRYHQGRDVDFEATWEAVRGIVLKKFAGPYDKGEYSPSVQKTLYDIQVLSLSQLPEIEDMEISLPNIHYFNIDMSKMGLINKEEVLLPLDNPYGRITGTVKRKLTSRL(SEQ ID NO:5)。
[0047] MAHYHNDYKKNDEVEFVRTGYGKDMVKVLHIQRDGKYHSIKEVATSVQLTLSSKKDYLHGDNSDIIPTDTIKNTVHALAKFKGIKSIEAFAVNICQHFLSSFNHVIRTQVYVEEIPWKRLEKNGVKHVHAFIHTPTGTHFCEVEQLRSGPPVIH SGIKDLKVLKTTQSGFEGFIKDQFTTLPEVKDRCFAAQVYCKWRYHQCRDVDFEATWDTIRDVVLEKFAGPYDKGEYSPSVQKTLYDIQVVSLSQVPEIDDMEISLPNIHYFNIDMSKMGLINKEEVLLPLDNPYGKITGTVKRKLSSRL(SEQ ID NO:6).
[0048] MADYHNNYKKNDELEFVRTGYGKDMVKVLHIQRDGKYHSIKEVATSVQLTLSSKKDYLHGDNSDIIPTDTIKNTVHVLAKFKGIKSIEAFGVNICEYFLSSFNHVIRAQVYVEEIPWKRLEKNGVKHVHAFIHTPTGTHFCEVEQLRSGPPVIH SGIKDLKVLKTTQSGFEGFIKDQFTTLPEVKDRCFATQVYCKWRYHQCRDVDFEATWGTIRDLVLEKFAGPYDKGEYSPSVQKTLYDIQVLSLSRVPEIEDMEISLPNIHYFNIDMSKMGLINKEEVLLPLDNPYGKITGTVKRKLSSRL(SEQ ID NO:7).
[0049] Among them, the amino acid sequence shown in SEQ ID NO:1 is the amino acid sequence of a chimeric uricase derived from pig and baboon (pig baboon); the amino acid sequence shown in SEQ ID NO:2 is the amino acid sequence of pig uricase; the amino acid sequence shown in SEQ ID NO:3 is the amino acid sequence of a chimeric uricase derived from dog and baboon (dog baboon); the amino acid sequence shown in SEQ ID NO:4 is the amino acid sequence of dog uricase; the amino acid sequence shown in SEQ ID NO:5 is the amino acid sequence of bovine uricase; the amino acid sequence shown in SEQ ID NO:6 is the amino acid sequence of monkey uricase; and the amino acid sequence shown in SEQ ID NO:7 is the amino acid sequence of baboon uricase.
[0050] It should be noted that the positioning of lysine in the present application is based on the amino acid sequence shown in SEQ ID NO: 1, such as K 4 Refers to the lysine at position 4 based on the amino acid sequence shown in SEQ ID NO:1. The uricase having the amino acid sequence shown in SEQ ID NO:1-7 or a polypeptide having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99% identity with SEQ ID NO:1-7; or a polypeptide having one or more amino acid substitutions, deletions and / or additions compared to SEQ ID NO:1-7 has structural homology, and those skilled in the art can determine the corresponding T on SEQ ID NO:2-7 or a polypeptide having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99% identity with SEQ ID NO:1-7 or a polypeptide having one or more amino acid substitutions, deletions and / or additions compared to SEQ ID NO:1-7 through sequence alignment. 1 , K 3 , K 4 , K 30 , K 35 , K 76 , K 79 , K 97 , K 112 , K 116 , K 120 , K 152 , K 179 , K 222 , K 231 , K 266 , K 272 , K 285 , K 291 , K 293 The corresponding site of the site is then PEG-modified at the corresponding site on the above-mentioned polypeptide, thereby achieving the advantages of low immunogenicity, high in vivo stability and suitability for intramuscular injection of the polyethylene glycol-modified urate oxidase of the present application.
[0051] For example, according to an embodiment of the present invention, the sequence shown in SEQ ID NO: 2 is T-terminal to the sequence shown in SEQ ID NO: 1. 1 , K 3 , K 4 , K 30 , K 35 , K 76 , K 79 , K 97 , K 112 , K 116 , K 120 , K 152, K 179 , K 222 , K 231 , K 266 , K 272 , K 285 , K 291 , K 293 The corresponding sites of the site include M 1 , K 9 , K 10 , K 36 , K 41 , K 82 , K 85 , K 103 , K 118 , K 122 , K 126 , K 158 , K 185 , K 228 , K 237 , K 272 , K 278 , K 297 , K 299 ; The corresponding sites of the sequence shown in SEQ ID NO:3 and the corresponding sites of the sequence shown in SEQ ID NO:1 include M 1 , K 3 , K 29 , K 34 , K 75 , K 78 , K 111 , K 115 , K 119 , K 151 , K 178 , K 221 , K 230 , K 265 , K 271 , K 284 , K 290 , K 292 ; The corresponding sites of the sequence shown in SEQ ID NO:4 and the corresponding sites of the sequence shown in SEQ ID NO:1 include M 1 , K 9 , K 10 , K 36 , K 41 , K 82 , K 85 , K 118 , K 122 , K 126 , K 158 , K 185 , K 228 , K 237 , K 272 , K278 , K 297 , K 299 ; The corresponding sites of the sequence shown in SEQ ID NO:5 and the corresponding sites of the sequence shown in SEQ ID NO:1 include M 1 , K 10 , K 36 , K 41 , K 82 , K 85 , K 118 , K 122 , K 126 , K 158 , K 185 , K 228 , K 237 , K 272 , K 278 , K 297 , K 299 ; The corresponding sites of the sequence shown in SEQ ID NO:6 and the corresponding sites of the sequence shown in SEQ ID NO:1 include M 1 , K 9 , K 10 , K 36 , K 41 , K 82 , K 85 , K 118 , K 122 , K 126 , K 158 , K 185 , K 228 , K 237 , K 272 , K 278 , K 291 , K 297 , K 299 ; The corresponding sites of the sequence shown in SEQ ID NO:7 and the corresponding sites of the sequence shown in SEQ ID NO:1 include M 1 , K 9 , K 10 , K 36 , K 41 , K 82 , K 85 , K 118 , K 122 , K 126 , K 158 , K 185 , K 228 , K 237 , K 272 , K 278 , K 291 , K 297 , K 299The inventors have found through experiments that after PEG modification of at least 11 of the corresponding sites of the amino acid sequences shown in SEQ ID NOs: 2 to 7, the obtained PEG-modified urate oxidase has the advantages of low immunogenicity, high in vivo stability, and suitability for intramuscular injection.
[0052] According to an embodiment of the present invention, the peptide map of the polyethylene glycol-modified uricase is compared with the peptide map of the uricase not modified by polyethylene glycol, and the relative proportion of the peak area reduction of at least 11 predetermined peptide segments is not less than 75%, preferably not less than 80%, and more preferably not less than 90%. The polyethylene glycol-modified uricase according to an embodiment of the present invention has the advantages of low immunogenicity, high in vivo stability, and suitability for intramuscular injection.
[0053] According to an embodiment of the present invention, the peptide map of the polyethylene glycol-modified uricase has the peak area-reduced peptide segments shown in Table 8.
[0054] According to an embodiment of the present invention, the peptide map of the polyethylene glycol-modified uricase is as follows: Figure 6 or Figure 7 shown.
[0055] In a second aspect of the present invention, a method for reducing the immunogenicity of uricase is provided. According to an embodiment of the present invention, at least 11 of the following amino acid sites of the polyethylene glycol-modified uricase are PEG-modified, T 1 , K 3 , K 4 , K 30 , K 35 , K 76 , K 79 , K 97 , K 112 , K 116 , K 120 , K 152 , K 179 , K 222 , K 231 , K 266 , K 272 , K 285 , K 291 , K 293 The method comprises: coupling uricase and polyethylene glycol, wherein the polyethylene glycol is provided in the form of an acidic solution, and the molar ratio of the uricase to the polyethylene glycol is 1:(56-94); according to the method of the embodiment of the present invention, the immunogenicity of uricase can be effectively reduced, and the obtained uricase has higher in vivo safety and longer-lasting effect.
[0056] It can be understood that the additional technical features of the method for preparing polyethylene glycol-modified uricase and the technical effects of the additional technical features described above are applicable to the additional technical features of the method for reducing the immunogenicity of uricase according to an embodiment of the present invention, and the additional technical features of the method for reducing the immunogenicity of uricase according to an embodiment of the present invention are not described in detail here.
[0057] In the third aspect of the present invention, the present invention provides a polyethylene glycol-modified uricase. According to an embodiment of the present invention, the uricase is obtained by the method described above. The polyethylene glycol-modified uricase according to the embodiment of the present invention can greatly improve the in vivo stability of uricase and reduce immunogenicity under the premise of ensuring the enzyme activity to the maximum extent, and the in vivo efficacy after intramuscular injection can reach the equivalent in vivo efficacy of similar drugs on the market after intravenous injection.
[0058] In a fourth aspect of the present invention, the present invention provides a pharmaceutical composition. According to an embodiment of the present invention, the pharmaceutical composition comprises the urate oxidase described above. The pharmaceutical composition according to an embodiment of the present invention has the advantages of low immunogenicity, high in vivo stability, and suitability for intramuscular injection, and can be used for the treatment or prevention of hyperuricemia-related diseases.
[0059] According to an embodiment of the present invention, the pharmaceutical composition further comprises at least one of the following additional technical features:
[0060] According to an embodiment of the present invention, the pharmaceutical composition further comprises a pharmaceutically acceptable adjuvant.
[0061] According to an embodiment of the present invention, the pharmaceutical composition further comprises other drugs for treating or preventing diseases related to hyperuricemia.
[0062] In a fifth aspect of the present invention, the present invention provides the use of the above-mentioned uricase or the above-mentioned pharmaceutical composition in the preparation of a drug, wherein the drug is used to treat hyperuricemia-related diseases and reduce the level of uric acid in the biological fluid of a subject in need. The uricase according to the embodiment of the present invention has the advantages of low immunogenicity, high in vivo stability and suitability for intramuscular injection, and has significant advantages in the treatment of hyperuricemia-related diseases.
[0063] According to an embodiment of the present invention, the above-mentioned use may further include at least one of the following additional technical features:
[0064] According to an embodiment of the present invention, the hyperuric acid-related diseases include those selected from chronic hyperuricemia, gout, kidney disease, hyperuricemia arthritis, kidney stones, gouty nodules, hypertension, diabetes, hypertriglyceridemia, metabolic syndrome, and coronary heart disease.
[0065] According to an embodiment of the present invention, the biological fluid is urine or blood. BRIEF DESCRIPTION OF THE DRAWINGS
[0066] Figure 1 This is a PHC physical and chemical reference substance-SEC-HPLC-UV detection diagram according to an embodiment of the present invention;
[0067] Figure 2 This is a PHC physical and chemical reference substance-SEC-HPLC-RI detection diagram according to an embodiment of the present invention;
[0068] Figure 3 This is a PEG reference substance-SEC-HPLC-RI detection diagram according to an embodiment of the present invention;
[0069] Figure 4 This is a SEC-HPLC-UV detection diagram of the PU5 modified product according to an embodiment of the present invention;
[0070] Figure 5 This is a SEC-HPLC-RI detection diagram of the PU5 modified product according to an embodiment of the present invention;
[0071] Figure 6 is a comparison diagram of PHC and PU5 respectively digested by Lys-c and trypsin according to an embodiment of the present invention;
[0072] Figure 7 is a PU5 Lyc cleavage map according to an embodiment of the present invention;
[0073] Figure 8 is the serum uric acid level of model rats after intramuscular administration of different doses according to an embodiment of the present invention;
[0074] Fig. 9 is a kidney injury necrosis and inflammation scoring diagram according to an embodiment of the present invention;
[0075] Fig.10 is a graph showing the average blood drug concentration-time curve of each group after a single intravenous injection of the same dose (1.0 mg / kg) of Pegloticase and Pegylated Uricase Injection to SD rats according to an embodiment of the present invention;
[0076] Fig.11 is a graph showing the average blood drug concentration-time curves of each group after a single intramuscular injection of Pegloticase and different doses of pegylated uricase injection in SD rats according to an embodiment of the present invention;
[0077] Fig.12 is a graph showing the average blood drug concentration-time curves of each group after a single intramuscular injection of different doses of pegylated uricase injection in SD rats according to an embodiment of the present invention;
[0078] Fig.13 is a graph showing the average blood uric acid level-time curves of the SD rats at different times after a single intramuscular / intravenous injection of different doses of Pegloticase and pegylated uricase injection according to an embodiment of the present invention;
[0079] Fig.14 is a graph showing the average blood drug concentration-time curve of male and female SD rats after the first intravenous injection (Day 1) of the same dose (1.0 mg / kg) of Pegloticase and Pegylated Uricase Injection according to an embodiment of the present invention;
[0080] Fig.15 It is a graph of the average blood drug concentration-time curve of male and female SD rats after the last intravenous injection (Day 22) of the same dose (1.0 mg / kg) of Pegloticase and Pegylated Uricase Injection according to an embodiment of the present invention;
[0081] Fig.16 is a graph showing the average blood drug concentration-time curve of male and female SD rats after the first intramuscular injection (Day 1) of the same dose (1.0 mg / kg) of Pegloticase and Pegylated Uricase Injection according to an embodiment of the present invention;
[0082] Fig.17 It is a graph of the average blood drug concentration-time curve of male and female SD rats after the last intramuscular injection (Day 22) of the same dose (1.0 mg / kg) of Pegloticase and Pegylated Uricase Injection according to an embodiment of the present invention;
[0083] Fig.18 is a graph of the mean value of blood uric acid at different times after multiple intravenous injections of Pegloticase and pegylated uricase injection in SD rats according to an embodiment of the present invention; and
[0084] Fig.19 This is a curve diagram of the average blood uric acid level at different times after multiple intramuscular injections of Pegloticase and pegylated uricase injection in SD rats according to an embodiment of the present invention. DETAILED DESCRIPTION
[0085] Embodiments of the present invention are described in detail below, and examples of the embodiments are shown in the accompanying drawings. The embodiments described below with reference to the accompanying drawings are exemplary and intended to be used to explain the present invention, but should not be understood as limiting the present invention.
[0086] The object of the present invention is to provide a method for preparing polyethylene glycol-modified uricase.
[0087] Another object of the present invention is to provide a novel polyethylene glycol-modified urate oxidase.
[0088] Another object of the present invention is to provide a method for effectively reducing the immunogenicity of urate oxidase. This technology can effectively reduce the immunogenicity of urate oxidase and improve the in vivo safety and stability of urate oxidase.
[0089] Another object of the present invention is to provide an application of the polyethylene glycol oxidized uricase conjugate obtained as above, which can achieve the effect of long-term and significant reduction of blood uric acid levels in vivo, and can be used for the treatment of hyperuricemia and gout.
[0090] As used herein, the terms "uricase" and "uricase" are used interchangeably and refer to a class of enzymes described in the present invention that can catalyze the oxidation of uric acid to produce allantoin and hydrogen peroxide. The terms "uricase analogs", "uricase analogs", and "uricase derivatives" are used interchangeably and refer to structural modifications such as partial amino acid substitution, deletion or addition to the protein structure sequence of uricase while retaining the activity of uricase catalyzing the conversion of uric acid to allantoin and hydrogen peroxide, thereby achieving the effects of this example, including but not limited to reducing immunogenicity, increasing protein stability, and facilitating further polyethylene glycol modification.
[0091] There is no particular limitation on the uricase, and the uricase may be from any source and its analogs. Representative examples include but are not limited to mammalian sources, microorganisms, plants, and the like.
[0092] In another preferred embodiment, the uricase and uricase analogs thereof are derived from mammals, preferably the amino acid sequences shown in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 4, and more preferably SEQ ID NO: 1.
[0093] The urate oxidases from different species described in the present invention can be obtained through various ways, including but not limited to natural extraction, chemical synthesis, genetic engineering recombinant expression, etc.
[0094] In another preferred embodiment, the uricase protein sequence (SEQ ID NO: 1) is recombinantly expressed in a host cell by recombinant technology.
[0095] In another preferred embodiment, the recombinant expression strain is prepared by using Escherichia coli or yeast as a host, and more preferably, Escherichia coli is used as a host strain for recombinant expression.
[0096] As used herein, the polyethylene glycol uricase of the present invention refers to a uricase obtained by covalently modifying uricase with polyethylene glycol. The polyethylene glycol (PEG) refers to a mixture of ethylene oxide condensation products and water, represented by the general formula H(OCH2CH2)nOH, which is a pH neutral, non-toxic, highly water-soluble hydrophilic polymer with a linear or branched structure. Due to the non-toxicity and good biocompatibility of PEG, the FDA has approved a variety of PEG-modified recombinant protein drugs for marketing, proving that PEG can be used to reduce the immunogenicity of proteins, increase the solubility of proteins and extend the half-life of proteins. In order for PEG to bind to proteins, one or more ends of PEG need to be activated, and the corresponding modification groups can be selected for activation according to the modified target protein, such as amino, sulfhydryl, carboxyl or hydroxyl.
[0097] In another preferred embodiment, the site for PEG modification of oxidative uricase and uricase analogs of the present invention is the epsilon amino group of lysine residues, but there is also a small amount of modification of the alpha amino group of N-terminal lysine residues. Urate oxidase is covalently linked to the modified group of PEG through an aminoester bond, a secondary amino bond or an amide bond, preferably the polyethylene glycol molecule is coupled to the uricase to form an amide bond, and the modified group of the polyethylene glycol includes but is not limited to N-hydroxysuccinimides, including but not limited to N-hydroxysuccinimide (NHS), N-hydroxysuccinimide carbonate (SC), N-hydroxysuccinimide acetate (SCM), N-hydroxysuccinimide propionate (SPA), N-hydroxysuccinimide butyrate (SBA), N-hydroxysuccinimide succinate (SS), etc., wherein the blocking group of polyethylene glycol includes but is not limited to monomethoxy, ethoxy, glucose or galactose, preferably monomethoxy.
[0098] In another preferred embodiment, the polyethylene glycol can be a straight chain or a linear chain.
[0099] In another preferred embodiment, the relative molecular weight of polyethylene glycol used in polyethylene glycol uricase is no more than 6KD, preferably 1KD to 5KD, and most preferably 5KD. It should be noted that the "relative molecular weight of polyethylene glycol" described in this application refers to the relative molecular weight of polyethylene glycol without a modification group, which has the general meaning in the art. The total relative molecular weight of PEG after activation by an activation group is slightly greater than 5KD, such as within the range of 5KD+10%.
[0100] In another preferred embodiment, the polyethylene glycol-modified uricase has the following characteristics:
[0101] (1) At least 11 of the following amino acid sites in uricase are PEGylated,
[0102] T 1 , K 3 , K 4, K 30 , K 35 , K 76 , K 79 , K 97 , K 112 , K 116 , K 120 , K 152 , K 179 , K 222 , K 231 , K 266 , K 272 , K 285 , K 291 , K 293 .
[0103] (2) One uricase molecule is coupled to an average of 11 to 13 polyethylene glycol molecules.
[0104] (3) Contains K in the uricase sequence of Seg ID NO:1 30 and / or K 35 , and K 222 and / or K 231 Polyethylene glycol coupling modification occurs.
[0105] (4) Polyethylene glycol urate oxidase has lower in vivo immunogenicity.
[0106] In another aspect of the present invention, a method for effectively reducing the immunogenicity of uricase is provided. This technology can effectively reduce the immunogenicity of uricase and improve the in vivo stability of uricase.
[0107] As used herein, the polyethylene glycol-modified uricase is characterized in that: the uricase is not particularly limited and can be uricase from any source and uricase analogs thereof, representative examples of which include but are not limited to mammalian sources, microorganisms, plants, etc.
[0108] In another preferred embodiment, the uricase and uricase analogs thereof are derived from mammals, preferably the amino acid sequences of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 4, and more preferably SEQ ID NO: 1.
[0109] The urate oxidases from different species described in the present invention can be obtained through various ways, including but not limited to natural extraction, chemical synthesis, genetic engineering recombinant expression, etc.
[0110] In another preferred embodiment, Escherichia coli or yeast is used as a host to construct a recombinant expression strain, and more preferably, Escherichia coli is used as a host strain for recombinant expression.
[0111] The uricase described in the present invention can be recombinantly expressed in Escherichia coli to obtain a large amount of uricase, and the expressed uricase can be expressed intracellularly, on the cell membrane, or secreted outside the cell. If necessary, high-purity uricase can be obtained by methods well known to those skilled in the art. Examples of these methods include, but are not limited to, centrifugation, bacterial disruption, salting out, ultrafiltration, ion exchange chromatography, hydrophobic chromatography, molecular sieve chromatography, and other various techniques combined.
[0112] The uricase obtained above can be covalently bound to polyethylene glycol via a linker group using methods known in the art.
[0113] In another preferred embodiment, polyethylene glycol is used to modify the lysine residues on the surface of the spatial structure of uricase. Urate oxidase is covalently linked to the modifying group (also referred to as the active group) of PEG through an amide bond, and the modifying group (also referred to as the active group) of polyethylene glycol includes but is not limited to N-hydroxysuccinimide (NHS), N-hydroxysuccinimide carbonate (SC), N-hydroxysuccinimide acetate (SCM), N-hydroxysuccinimide propionate (SPA), N-hydroxysuccinimide butyrate (SBA), N-hydroxysuccinimide succinate (SS), wherein the blocking group of polyethylene glycol includes but is not limited to monomethoxy, ethoxy, glucose or galactose, preferably monomethoxy.
[0114] In another preferred embodiment, the polyethylene glycol may be a linear or branched chain.
[0115] In another preferred embodiment, the relative molecular weight of polyethylene glycol is no more than 6KD, preferably 1KD to 5KD, more preferably 2KD, 5KD, and most preferably 5KD.
[0116] In another preferred embodiment, the present invention provides a method for preparing polyethylene glycol-modified uricase, having one or more of the following characteristics:
[0117] (1) The molar ratio of uricase oxidase to polyethylene glycol is 1:45 to 1:150 (uricase oxidase: polyethylene glycol), preferably 1:45 to 1:110, and more preferably 1:56 to 1:94.
[0118] (2) The coupling reaction system is a carbonate buffer solution, and its modified pH range is 9 to 11.
[0119] (3) The urate oxidase protein concentration in the coupling reaction system was 10 mg / ml.
[0120] The method for preparing the polyethylene glycol-modified uricase adopts a variety of purification methods to obtain high-purity polyethylene glycol-modified uricase.
[0121] In another preferred embodiment, the purification of the modified sample adopts methods including but not limited to molecular sieve chromatography, ion exchange chromatography, hydrophobic chromatography, tangential flow ultrafiltration, or a combination thereof, more preferably molecular sieve chromatography and tangential flow ultrafiltration.
[0122] In another aspect of the present invention, a polyethylene glycol-modified urate oxidase and its application are provided. The conjugate can achieve the effect of long-term and significant reduction of blood uric acid level in vivo, and can be used for the treatment of hyperuricemia and urinary tract infections.
[0123] The polyethylene glycol urate oxidase is more suitable as a drug and a composition thereof for treating chronic hyperuricemia or gout. The main symptoms of hyperuricemia and gout include but are not limited to uric acid nephropathy and gout arthritis.
[0124] The administration routes of the polyethylene glycol urate oxidase include but are not limited to intravenous injection, subcutaneous injection, intramuscular injection and intraperitoneal injection, etc., preferably intravenous injection and intramuscular injection, more preferably intramuscular injection.
[0125] The polyethylene glycol uricase has lower in vivo immunogenicity.
[0126] The low immunogenicity of the polyethylene glycol urate oxidase means that after intramuscular injection of polyethylene glycol urate oxidase in a human or animal body, the body does not produce antibodies against polyethylene glycol molecules or produces low titer antibodies against polyethylene glycol molecules. No antibodies against urate oxidase are produced.
[0127] The polyethylene glycol urate oxidase has a longer half-life in vivo and the effect of reducing the uric acid level in the body after intramuscular injection.
[0128] According to some embodiments of the present invention, the pharmaceutical composition comprising the polyethylene glycol-modified uricase of the present invention may also include a pharmaceutically acceptable carrier, and the dosage form and administration mode of the pharmaceutical composition are not particularly limited. For injection preparations, the pharmaceutically acceptable carrier may include a buffer, a preservative, an analgesic, a solubilizer, an isotonic agent and a stabilizer. For preparations for topical administration, the pharmaceutically acceptable carrier may include an alkali, an excipient, a lubricant and a preservative. The pharmaceutical composition of the present invention can be combined with the above-mentioned pharmaceutically acceptable carrier to be prepared into various dosage forms.
[0129] Among them, according to some specific examples of the present invention, excipients and diluents in carriers suitable for pharmaceutical formulations may include: lactose, glucose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum arabic, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate and mineral oil.
[0130] According to other embodiments of the present invention, the pharmaceutical composition of the present invention may further include fillers, anticoagulants, lubricants, buffers, osmotic pressure regulators, moisturizers, fragrances, preservatives, and the like.
[0131] According to the embodiments of the present invention, the polyethylene glycol-modified uricase and the pharmaceutical composition of the present invention can greatly improve the in vivo stability of uricase and reduce the immunogenicity under the premise of ensuring the enzyme activity to the maximum extent, and the in vivo efficacy after intramuscular injection can reach the in vivo efficacy of the original drug after intravenous injection. Therefore, the polyethylene glycol-modified uricase and the pharmaceutical composition comprising the polyethylene glycol-modified uricase of the present invention can be administered for the treatment or prevention of hyperuricemia-related diseases.
[0132] The term "administration" as used herein refers to the introduction of a predetermined amount of a substance into a patient by a suitable means. The polyethylene glycol-modified uricase of the present invention can be administered by any common route as long as it can reach the desired tissue. Various modes of administration are contemplated, including peritoneal, intravenous, intramuscular, subcutaneous, cortical, oral, topical, nasal, pulmonary and rectal administration, but the present invention is not limited to these exemplified modes of administration. However, due to oral administration, the active ingredient of the oral administration composition should be coated or formulated to prevent it from being degraded in the stomach. Preferably, the composition of the present invention can be administered in an injectable preparation. In addition, the pharmaceutical composition of the present invention can be administered using a specific device that delivers the active ingredient to the target cell.
[0133] The administration frequency and dosage of the pharmaceutical composition of the present invention can be determined by a number of relevant factors, including the type of disease to be treated, the administration route, the patient's age, sex, weight and severity of the disease, and the type of drug as the active ingredient.
[0134] The term "therapeutically effective amount" refers to an amount of a compound sufficient to significantly improve certain symptoms associated with a disease or condition, that is, an amount that provides a therapeutic effect for a given condition and dosing regimen. For example, in the treatment of chronic hyperuricemia or gout, a drug or compound that reduces, prevents, delays, inhibits or blocks any symptom of a disease or condition should be therapeutically effective. A therapeutically effective amount of a drug or compound does not need to cure a disease or condition, but will provide treatment for the disease or condition so that the onset of the individual's disease or condition is delayed, stopped or prevented, or the symptoms of the disease or condition are alleviated, or the duration of the disease or condition is changed, or, for example, the disease or condition becomes less severe, or recovery is accelerated.
[0135] The term "treatment" is used to refer to obtaining a desired pharmacological and / or physiological effect. The effect may be preventive in terms of completely or partially preventing a disease or its symptoms, and / or may be therapeutic in terms of partially or completely curing a disease and / or the adverse effects caused by the disease. "Treatment" as used herein covers the treatment of mammals, especially human diseases (mainly hyperuricemia-related diseases), including: (a) preventing the disease in individuals who are susceptible to the disease but have not yet been diagnosed with the disease; (b) inhibiting the disease, such as blocking the progression of the disease; or (c) alleviating the disease, such as alleviating symptoms associated with the disease. "Treatment" as used herein covers any medication that administers a drug or compound to an individual to treat, cure, alleviate, improve, reduce or inhibit an individual's disease, including but not limited to administering a polyethylene glycol-modified uricase as described herein to an individual in need.
[0136] According to an embodiment of the present invention, the polyethylene glycol-modified uricase or pharmaceutical composition of the present invention can be used in combination with conventional treatment methods and / or therapies, or can be used separately from conventional treatment methods and / or therapies. When the polyethylene glycol-modified uricase or pharmaceutical composition of the present invention is administered in a combination therapy with other drugs, they can be administered to an individual sequentially or simultaneously. Alternatively, the pharmaceutical composition of the present invention can include a combination of the polyethylene glycol-modified uricase of the present invention, a pharmaceutically acceptable carrier or a pharmaceutically acceptable excipient, and other therapeutic or preventive drugs known in the art.
[0137] The term "average degree of modification" refers to the number of PEGs attached to each uricase monomer.
[0138] In this article, unless otherwise specified, the expression "amino acid site is PEG-modified" means that in the three-dimensional structure of the corresponding polypeptide, the PEG molecule covers the amino acid site, so that at least a portion of the group at the amino acid site is not exposed. It can be understood by those skilled in the art that they can determine whether a specific amino acid site is modified by a PEG molecule by conventional technical means, for example, they can refer to the method listed in the "Polyethylene glycol modification site detection" section of Example 3 of this application for identification. In brief, the method comprises: 1) digesting the non-PEGylated and PEGylated uricases with one or more enzymes, such as Lys-C or Trypsin for single digestion, or Lys-C and Trypsin for double digestion; 2) separating the digested fragments by high performance liquid chromatography to generate chromatograms of the non-PEGylated and PEGylated uricases, i.e., peptide maps; 3) comparing the differences between the peptide maps of the non-PEGylated and PEGylated uricases, and determining the relative proportion of the reduction or disappearance of the peak of the peptide segment at the specific amino acid site in the PEGylated uricase in combination with a predetermined internal standard peptide segment, thereby determining whether the specific amino acid site on the peptide segment is PEG-modified. Specifically, in Example 3 of the present application, the relative proportion of the reduction or disappearance of the peak area of the peptide segment at the specific amino acid site can be calculated by the following formula:
[0139] P(%)=(A2-A1) / A2×100%,
[0140] Where A1=A0×t
[0141] A0 is the measured peak area of the peptide at the specific amino acid site of the modified protein to be tested, and t is the average value of the peak area ratio of the internal reference peptide in the PHC peptide map and the modified protein peptide map to be tested;
[0142] P (%) represents the relative proportion of the reduction or disappearance of the peak area of the peptide at the specific amino acid site, A2 is the peak area of the peptide at the specific amino acid site in the PHC peptide map, and A1 is the peak area of the peptide at the specific amino acid site in the peptide map of the modified protein to be tested after conversion by the internal reference.
[0143] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the various technical features specifically described below (such as embodiments) can be combined with each other to form a new or preferred technical solution, which can be more clearly understood by referring to the following examples. Due to space limitations, the examples are only for illustrative purposes and are not intended to limit the present invention.
[0144] Embodiments of the present invention will be described in further detail below, examples of which are shown in the accompanying drawings. The embodiments described below with reference to the accompanying drawings are exemplary and intended to be used to explain the present invention, but should not be construed as limiting the present invention.
[0145] Example 1 Preparation of recombinant uricase
[0146] 1.1 Construction of genes and expression plasmids for uricase expression
[0147] According to the E. coli codon usage preference data, combined with codon preference and GC content, the cDNA sequence of uricase protein (code: PHC) (SEQ ID NO: 1) was designed, and the whole gene was synthesized and named pUC-57-PHC plasmid. Nde I and BamH I were used as the target gene insertion sites, and pET-30a plasmid was used as the expression vector (pET-30a-PHC).
[0148] 1.2 Transformation of expression plasmids into bacterial host cells
[0149] The expression vector pET-30a-PHC was introduced into Escherichia coli BL21 (DE3) using the CaCl2 method, and Kanamycin was used for resistance screening to select high-expression clones, and the original seed bank strain (E3B) was preserved. These steps were implemented according to common methods in the field of molecular biology.
[0150] 1.3 Preparation of recombinant uricase
[0151] The transformed engineered strains were fermented and expressed in a fermenter under the following conditions: first cultured at 30°C and pH about 7.2 until OD 600 =30 or above, then raise the temperature to about 37°C, add IPTG to 0.5 mmol / L, and continue induction for more than 3 hours to allow urate oxidase to accumulate. Collect the cells by centrifugation and store them below -15°C.
[0152] Take the frozen bacterial cells and suspend them in 25mmol / L Tris, 5mmol / L EDTA buffer at a suspension ratio of 1:10 (W / V). After breaking the bacterial cells with high pressure, collect the uricase precipitate by centrifugation, wash the precipitate once with 50mmol / L NaHCO3, and suspend the enriched uricase precipitate in 100mmol / L Na2HCO3 (pH9.7-10.3) buffer at a suspension ratio of 1:50 (W / V), stir at room temperature overnight to dissolve, and then collect the supernatant by centrifugation.
[0153] Urate oxidase was further purified through several chromatographic steps. The purity was greater than 95% as detected by SDS-PAGE and greater than 95% as detected by Superdex 200 column. The protein concentration was determined by Lowry method and the activity of uricase was determined by spectrophotometer. One unit (U) of enzyme activity was defined as the amount of enzyme required to convert 1 μmol of uric acid per minute under the conditions of reaction temperature of 37°C and optimal buffer pH of 9.0.
[0154] Example 2 Preparation of PEGylated Oxidative Uricase
[0155] Monomethoxy PEG derivatives of different molecular weights (500-20000Da), such as 5K molecular weight N-succinimidyl propionate PEG (5K-PEG-SPA), are dissolved in 1-5mmol / L acid solution to form a 100-300mmol / L PEG solution. After dissolution, the solution is added to a carbonate buffer solution with a carbonate concentration of 0.1-0.3mol / L pH 10.0 containing urate oxidase at a molar ratio of 1:45-1:150 (uricase: 5K-PEG-SPA), so that PEG and uricase undergo coupling reaction. The concentration of uricase oxidase in the coupling reaction is 10mg / ml. The coupling reaction needs to be stirred at 5-30℃ for more than 60 minutes until the degree of PEG coupling no longer changes with time. After the reaction is completed, unmodified PEG and by-products are removed from the reaction by ultrafiltration and / or chromatography. A suitable molecular sieve chromatography medium can be selected to separate and remove the modified by-products. Finally, the 5K-modified PEGylated uricase (code-named PU5) was obtained by sterile filtration.
[0156] Example 3 Characteristic Analysis of Pegylated Oxidative Uricase
[0157] 3.1 Average modification degree and enzyme activity detection
[0158] The protein concentration was determined by Lowry method, and the activity of polyethylene glycol urate oxidase was determined under spectrophotometer. The maximum ultraviolet absorption wavelength of uric acid, the substrate of uricase, is 293nm, while the maximum ultraviolet absorption wavelength of the product allantoin is 224nm. Within a certain concentration range, the absorption value of uric acid at 293nm is proportional to its concentration, and the spectrophotometer method can be used for quantitative determination of uric acid. The specific process is as follows: turn on the UV-visible spectrophotometer, adjust the wavelength to 293nm, and turn on the water bath circulation system of the instrument to keep the temperature at 37℃. Use sodium tetraborate buffer as blank control and calibrate zero point; take 2.95ml substrate reaction solution (0.1mol / L sodium tetraborate, 100μmol / L uric acid, pH9.5, preheated at 37℃) and place it in a quartz colorimetric cup, then add 50μl of the test sample and mix quickly, and then measure the absorption value at 293nm. The absorbance change at 293 nm was continuously measured; the uric acid degradation concentration was calculated according to C=A / εL (where A is the absorbance of a specific concentration of uric acid at 293 nm, ε is the molar extinction coefficient of uric acid, L is the light path of the cuvette, and C is the molar concentration of uric acid), and the enzyme activity was calculated; definition of enzyme activity: at the optimum reaction temperature of 37°C and the optimum reaction pH of 9.5, the amount of enzyme required to convert 1 μmol uric acid into allantoin per minute was defined as one activity unit (U).
[0159] The average degree of modification of PEGylated uricase was detected by SEC-HPLC in series with UV / RI (combined ultraviolet and refractive index detector). The protein has a maximum absorption peak at 280nm ultraviolet, while PEG has no absorption at this wavelength. At the same time, the absorption values of protein and PEG in a certain range of the differential refractive index detector are proportional to their various concentrations. Therefore, the contents of PEG and protein in PEGylated uricase can be obtained by external standardization of PEG reference and PHC physical and chemical reference, and then the number of PEG molecules on each uricase monomer, i.e., the average degree of modification, can be obtained by the following calculation method.
[0160] Average degree of modification of PEG uricase = (relative molecular weight of uricase subunit × amount of PEG in sample) / (relative molecular weight of PEG × amount of protein in sample).
[0161] Among them, the SEC-HPLC-UV / RI detection chart of PHC physical and chemical reference, PEG reference, and PU5 modified product is shown in Figures 1 to 5 .
[0162] Example 2 Under different feed ratios, the enzyme activity and average modification degree of polyethylene glycol oxidizing uricase obtained are shown in Table 1.
[0163] Table 1: Enzyme activity and average degree of modification at different feed ratios under 5K-PEG
[0164] Protein: 5K-PEG feed molar ratio Enzyme activity Enzyme activity retention Average modification Unmodified uricase 11.4 U / mg 100% 0 1:48 10.71 U / mg 94% 10.3 1:56 11.17 U / mg 103.4% 11.4 1:68 12.2 U / mg 107.1% 11.9 1:82 12.02 U / mg 105.4% 12.3 1:94 11.75 U / mg 103.1% 12.1 1:110 10.83 U / mg 95% 11.5 1:150 10.03U / mg 88% 10.1
[0165] Example 2 The enzymatic activity and average degree of modification of polyethylene glycol oxidized uricase obtained at different PEG molecular weights and a protein to PEG feed molar ratio of 1:68 are shown in Table 2.
[0166] Table 2: Enzyme activity and average degree of modification under different molecular weight PEG modification
[0167]
[0168] Note: The average degree of modification indicates the number of PEG molecules per uricase monomer.
[0169] As can be seen from Tables 1 and 2, the average modification degree of the polyethylene glycol uricase of the present application is stable at more than 11, and the enzyme activity retention rate is high compared to the unmodified uricase, the enzyme activity does not decrease, but increases, and the enzyme activity is relatively stable. This is inconsistent with the view taught by the original drug that low molecular weight PEG modification will lead to reduced enzyme activity, and the polyethylene glycol-modified uricase obtained in the present application has a higher average modification degree of polyethylene glycol, and has achieved unexpected technical effects in terms of enzyme activity retention.
[0170] At the same time, the applicant also measured the immunogenicity of urate oxidase obtained under different molecular weight PEG modification, and the experimental results are shown in Table 3.
[0171] Table 3: In vivo antibody results of different molecular weight PEGylated urate oxidase in mice
[0172]
[0173]
[0174] In the experiment, mice were divided into groups, with 8 mice in each group. Each animal was intravenously administered with 1 mg / kg once a week. After four consecutive administrations, blood was collected for anti-PEG and anti-uricase immunogenicity assessment. It can be seen from the results in Table 3 that, under the condition of consistent average modification degree, as the PEG molecular weight increases, the positive rate of anti-PEG antibodies is higher. When the PEG molecular weight exceeds 5KD, the positive rate and antibody titer of anti-PEG antibodies increase significantly. From the analysis of the anti-uricase oxidase results, it can be seen that PEG modification can significantly reduce the antibody positive rate and antibody titer of uricase oxidase, and under the condition of consistent average modification degree, within the range of 2-5K, as the PEG molecular weight increases, the positive rate and antibody titer of anti-uricase oxidase antibodies are lower, and when the PEG molecular weight is greater than 5K, there is also a risk of anti-uricase antibodies. In summary, 2-5K PEG-modified uricase oxidase is better than 10KPEG-modified uricase oxidase group, and 5KD is more preferred.
[0175] Finally, the inventors simultaneously determined the enzymatic activity and average degree of modification of uricase obtained by modifying PEG under different acid dissolution conditions. The acid solution used can be selected from organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid, malonic acid, adipic acid, ascorbic acid, benzenesulfonic acid, benzoic acid, butyric acid, cyclopentylpropionic acid, digluconic acid, dodecylsulfuric acid, ethanesulfonic acid, formic acid, fumaric acid, glucoheptonic acid, glycerophosphate, gluconic acid, heptanoic acid, Hexanoic acid, 2-hydroxy-ethanesulfonic acid, lactobionic acid, lactic acid, lauric acid, lauryl sulfuric acid, malic acid, malonic acid, methanesulfonic acid, 2-naphthalenesulfonic acid, nicotinic acid, oleic acid, palmitic acid, pectinic acid, 3-phenylpropionate, picrate, pivalic acid, propionic acid, stearic acid, p-toluenesulfonic acid, undecanoic acid, valeric acid; can also be selected from inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, perchloric acid, hydroiodic acid, nitric acid, persulfuric acid, boric acid, dichromic acid, silicic acid, chromic acid, thiocyanic acid. Different types of acid solutions can achieve the dissolution of PEG and modify uricase. The feeding methods and feeding ratios of different PEGs are shown in Table 4 below.
[0176] Table 4: Effects of different feeding methods and feeding ratios on PEG modification results
[0177]
[0178]
[0179] The inventors found that the method of dissolving PEG in acid before feeding can obtain a higher protein modification rate and higher enzyme activity than directly feeding the dry powder, and effectively save the amount of PEG used.
[0180] 3.2 Detection of polyethylene glycol modification sites
[0181] In the following steps, the inventors detected the modification sites of the existing marketed products and the uricase obtained in the examples.
[0182] The PEG modification site of the polyethylene glycol modified uricase can be confirmed by digesting the non-PEGylated and PEGylated uricase with one or more enzymes, and then performing chromatographic detection to obtain a chromatogram, i.e., a peptide map. The non-PEGylated and PEGylated uricase can be digested with a single digestion (Lys-C or Trypsin) and / or a double digestion (Lys-C and Trypsin in combination). The digestion fragments are separated by a reverse phase column, and the modification site of the polyethylene glycol uricase and the polyethylene glycol modification percentage of the site are determined and calculated by comparing the disappearance or reduction ratio of the internal reference peptide segment.
[0183] Principle of modification site analysis in the mass peptide map of trypsin and Lys-C double digestion: Lys-C can specifically digest the C-terminus of lysine (K), and trypsin uses basic amino acids - arginine (R) and lysine (K) as digestion sites to specifically digest the C-terminal peptide bond. Compare the changes in the corresponding peptides before and after digestion in PHC and PU5, and combine with the internal standard peptide to analyze and confirm the relative proportion of the reduction or disappearance of the PEG-modified peptide. The relative percentage of the lysine site on the peptide modified by PEG can be determined by the relative proportion of the reduction or disappearance of the peptide, and whether a specific amino acid (such as lysine) on a specific peptide is modified by PEG can be obtained.
[0184] The details are as follows:
[0185] (1) Sample treatment: Dissolve uricase and pegylated uricase in enzyme digestion buffer (25mmol / L Tris-HCl, 20% acetonitrile, pH 9.0) to 1 mg / mL, take 100μL of each, add 2μL Lys-C, and digest at 37℃ for 4 hours. Then transfer the solution to a trypsin reaction tube (1:100 ratio) and continue digestion at 37℃ for 2 hours, continue reaction with 4μL TCEP reducing solution for 30 minutes, and then add 10μL 1mol / L hydrochloric acid solution to terminate the reaction.
[0186] (2) Analysis conditions:
[0187] Instruments: Thermo Ultimate 3000HPLC and MSQ Plus;
[0188] Chromatographic column: Yuexu Welch Materials (4.6mm×250mm, 5μm);
[0189] Analysis conditions: Solution A (0.1% TFA in water), Solution B (0.1% TFA in acetonitrile);
[0190] Gradient: 0-70 min, B from 3-70%;
[0191] LC detection wavelength: 214nm.
[0192] Ion source: ESI;
[0193] Ion type: positive ion;
[0194] Cone voltage: 50V;
[0195] Scanning range: 300-2000Da;
[0196] Scan time: 1s;
[0197] The post-column flow rate was about 0.3 mL / min.
[0198] The sample volume was 100 μL and the chromatogram was recorded.
[0199] (3) Result processing:
[0200] The chromatograms (peptide maps) of uricase and pegylated uricase were compared, and the relative proportions of the area reduction of the differential peptides were calculated.
[0201] (4) The experimental results are shown in Tables 5 to 8, and Figure 6-7 .
[0202] Table 5: PHC peptide fragments after Lys-C cleavage
[0203]
[0204]
[0205] Table 6: Peptide list after double digestion of PHC by Lys-C and trypsin
[0206]
[0207]
[0208] Calculation method for the percentage reduction of PU5 peptide peak area:
[0209] The following formula can be used to calculate the PU5 peptide peak area corresponding to the same concentration of PU5 and PHC:
[0210] A1=A0×t
[0211] Among them, A1 is the peak area of PU5 peptide segment after conversion of the two internal reference peptide segments, A0 is the measured peak area of PU5 peptide segment, and t is the average value of the peak area ratio of PHC peptide map to PU5 peptide map in internal reference peptide segments T30 and T31, which is 0.588.
[0212] Table 7: PHC and PU5 internal reference peptide comparison
[0213]
[0214] The relative percentage of the reduction in the peak area of a peptide segment in the PU5 peptide map can be calculated by using the following formula to convert the peak area of the peptide segment after internal reference conversion to the peak area of the PHC peptide map:
[0215] P(%)=(A2-A1) / A2×100%
[0216] Among them, A2 is the peak area of a certain peptide in the PHC peptide map, and A1 is the peak area of the peptide in the PU5 peptide map after internal reference conversion.
[0217] Table 8: Summary of peptides with reduced peak areas in peptide map after double enzyme digestion of PU5
[0218]
[0219]
[0220] According to the protein sequence analysis of this example (SEQ ID NO: 1), the potential sites for modification of urate oxidase are T 1 , K 3 , K 4 , K 17 , K 21 , K 30 , K 35 , K 48 , K 49 , K 66 , K 74 , K 76 , K 79 , K 97 , K 112 , K 116 , K 120 , K 152 , K 155 , K 158 , K 169 , K 179 , K 190 , K 215 , K 222 , K 231 , K 266 , K 272 , K 285 , K 291 , K 293 And so on 31 sites.
[0221] The analysis of the modification sites of the polyethylene glycol-modified uricase obtained in Example 2 shows that, as shown in Tables 5, 6, 7, 8 and Figure 6 The analysis showed that more than 90% of the peptides disappeared after PU5 digestion. 3 , K 4 , K 35 , K 97 , K 112 , K 116 , K 120 , K 152 , K 222 , K 266 , K 285 , the sites where the peptides disappeared within the range of 80% to 90% after PU5 digestion have K 76 , K 231 .
[0222] At the same time, the inventors found that the polyethylene glycol-modified uricase of the present application has more modification sites than the marketed drugs, and has significant differences. For example, through single enzyme digestion, it was found that the polyethylene glycol-modified uricase of the present application has more modification sites in K 30 , K 35 , K 222 and K 231 The disappearance ratio of peptides at the four sites is more than 80%, while the peptides at these four sites of the marketed similar drugs have almost not disappeared, that is, the marketed similar drugs have no significant difference in K 30 , K 35 , K 222 and K 231 The modification rates of the four sites are much lower than those of the polyethylene glycol-modified uricase of the present application. In addition, the polyethylene glycol-modified uricase of the present application has significantly lower immunogenicity than the marketed drugs. The inventors speculate that this may be related to the number of modified sites and the differences in the modified sites.
[0223] The in vivo animal evaluation of the polyethylene glycol-modified urate oxidase (PU5) of the present application will be described in detail below, wherein the pegloticase used in the experiment refers to a marketed similar drug with batch number 5085B.
[0224] Example 4 In vivo pharmacodynamic study of polyethylene glycol urate oxidase
[0225] 4.1. Evaluation of the efficacy of polyethylene glycol urate oxidase in model rats
[0226] The chronic hyperuricemia model of rats was induced by potassium oxonate drinking water combined with high uric acid diet, and the therapeutic effect of polyethylene glycol urate oxidase (PU5) on chronic hyperuricemia in rats was evaluated.
[0227] Forty model rats were selected and randomly divided into 4 groups, namely model group, low-dose pegylated uricase group (0.3 mg / kg), medium-dose pegylated uricase group (1.0 mg / kg), and high-dose pegylated uricase group (3.0 mg / kg), with 10 rats in each group, and 10 normal SD rats were selected as blank control group. The experiment was modeled for 5 consecutive weeks, and intramuscular administration began 1 week after modeling, once a week, for 4 consecutive weeks. The serum uric acid, serum urea nitrogen, and serum creatinine levels of the rats were detected before and 7 days after each administration, and the renal histological changes of the rats were observed after the end of the experiment.
[0228] Figure 8The results showed that on the 7th, 14th, 21st, 28th and 35th days after modeling, the blood uric acid levels in the model control group were significantly increased compared with those in the blank control group. Seven days after modeling, the serum urea nitrogen, creatinine and uric acid levels in the model group were 2.73 times, 2.40 times and 7.83 times those in the blank group, respectively. Fig. 9 As shown in the figure, the scores of tubular dilatation, necrosis, inflammation and fibrosis in the model control group were significantly increased, and the number of urate crystals was also significantly increased. The medium and high doses of the test substance pegylated uricase significantly reduced serum uric acid levels in a dose-dependent manner. During the period from 14 to 35 days, the average blood uric acid level in the medium dose group was maintained at 303.80-660.60 μmol / L, and the average blood uric acid level in the high dose group was maintained at 153.70-403.40 μmol / L. Compared with the model group, the blood uric acid level in the medium dose group decreased by 34.46-67.94%; the blood uric acid level in the high dose group decreased by 65.67-83.78%. Compared with the model control group, each group of pegylated uricase administration had a significant improvement on tubular dilatation, renal necrosis and inflammation.
[0229] 4.2. Evaluation of single-dose administration of polyethylene glycol urate oxidase in rats
[0230] Thirty-six SD rats were randomly divided into 6 groups (see Table 9), half of which were male and half were female, namely, intravenous injection group and intramuscular injection group of marketed drug Pegloticase, intravenous injection group of polyethylene glycol uricase, and intramuscular injection group of low, medium and high (0.5, 1.0, 2.0 mg / kg) doses of polyethylene glycol uricase. The specific dosing regimen and dose are shown in Table 9. Jugular vein blood was collected to test PK and PD.
[0231] Table 9: Animal grouping and dosage design
[0232]
[0233] 4.2.1. Pharmacokinetic comparison
[0234] The serum drug concentration levels of all individuals in SD rats before administration were lower than the lower limit of quantification (LLOQ: 312.500 ng / mL). After a single intramuscular injection of 0.5, 1.0, and 2.0 mg / kg, the serum drug concentration of pegloticase injection (PU5) was dose-related in the range of 0 to 168 h (0 to 7 days), and the overall level increased with the increase of the administration dose. After more than 168 h, the blood drug concentration of the pegloticase intramuscular administration group was lower than the lower limit of quantification, while the blood drug concentration of the PU5 intramuscular administration group could continue to be maintained for more than 240 h.
[0235] After administration, C levels in female and male SD rats in the 1.0 mg / kg pegloticase intravenous and intramuscular injection groups, 1.0 mg / kg pegloticase intravenous injection and 0.5, 1.0, 2.0 mg / kg pegloticase intramuscular injection groups were significantly increased. max (C 5min ) ratio is in the range of 0.75 to 0.99, AUC last The ratio is in the range of 0.54 to 0.94, and AUC 0-∞ The ratio was in the range of 0.58 to 0.97. It can be seen that there was no significant gender difference in the exposure level of Pegloticase and PU5 injection in SD rats.
[0236] However, the AUC of the group of SD rats given the same dose (1.0 mg / kg) of the marketed drug Pegloticase intravenously was last The AUC of the intramuscular injection group was 426.48±65.34. last The AUC of the PU5 injection intravenous group was 264.19±78.22. last The AUC of the intramuscular injection group was 565.61±161.60. last The AUC of PU5 was 337.86±227.34 under the same dose and administration method. last Higher than the marketed drug Pegloticase.
[0237] The t1 / 2(h) of the intravenous administration group of SD rats given the same dose (1.0mg / kg) of the marketed drug Pegloticase was 49.51±8.12, and the t1 / 2(h) of the intramuscular administration group was 55.21±13.50. The t1 / 2(h) of the intravenous administration group of PU5 injection was 86.12±33.82, and the t1 / 2(h) of the intramuscular administration group was 60.45±21.37. Under the same dose and the same administration method, the t1 / 2(h) of PU5 injection was longer than that of the marketed drug Pegloticase.
[0238] The above pharmacokinetic results are shown in Tables 10 to 15. Figure 10 to Figure 12 shown.
[0239] Table 10: Individual blood drug concentration data and statistical analysis data of SD rats after a single intravenous injection of 1.0 mg / kg Pegloticase (unit: μg / mL)
[0240]
[0241] Note: “ / ” indicates no relevant information.
[0242] Table 11: Individual blood drug concentration data and statistical analysis data of SD rats after a single intravenous injection of 1.0 mg / kg pegylated uricase injection (unit: μg / mL)
[0243]
[0244]
[0245] Note: “ / ” indicates no relevant information.
[0246] Table 12: Individual blood drug concentration data and statistical analysis data of SD rats after a single intramuscular injection of 1.0 mg / kg Pegloticase (unit: μg / mL)
[0247]
[0248] Note: “ / ” indicates no relevant information.
[0249] Table 13: Individual blood drug concentration data and statistical analysis data of SD rats after a single intramuscular injection of 1.0 mg / kg pegylated uricase injection (unit: μg / mL)
[0250]
[0251]
[0252] Table 14: Mean pharmacokinetic parameters of SD rats after single intravenous injection of Pegloticase and pegylated uricase injection
[0253]
[0254] Table 15: Mean pharmacokinetic parameters of Peglocticase and PEGylated uricase injection after single intramuscular injection in SD rats
[0255]
[0256]
[0257] 4.2.2. Comparison of in vivo efficacy (uric acid)
[0258] After a single intramuscular injection of 0.5, 1.0, and 2.0 mg / kg pegloticase injection, uric acid concentrations remained at a low level 1 and 3 days after administration, and uric acid levels in each dose group began to recover 7 days after administration. The higher the dose, the longer the uric acid remained at a low level in the body. Compared with the intravenous injection group of the same dose, the time that serum uric acid in the PU5 intravenous injection group maintained a low concentration level was longer than that in the pegloticase intravenous injection group. Compared with the intramuscular injection group of the same dose, the time that serum uric acid in the PU5 intramuscular injection group maintained a low concentration level was longer than that in the pegloticase intravenous injection group. Compared with the same dose group, the time that serum uric acid in the PU5 intravenous or intramuscular injection group maintained a low concentration level was longer than that in the pegloticase intravenous or intramuscular injection group, that is, the time that PU5 maintains a low concentration level in the body is longer than that of pegloticase. The results are as follows Fig.13 shown.
[0259] 4.3. Evaluation of Multiple-dose Polyethylene Glycol Urate Oxidase in Rats
[0260] This study set up 4 groups, namely the intravenous injection group and the intramuscular injection group of the marketed drug Pegloticase, the intravenous injection group and the intramuscular injection group of pegloticase injection (PU5), with 8 rats in each group, half of which were male and half were female, for a total of 32 SD rats. The intravenous injection group of Pegloticase and pegloticase injection was intravenous injection; the intramuscular injection group of Pegloticase and pegloticase injection was intramuscular injection. The dosage was 1.0 mg / kg. The drug was administered once a week for 4 consecutive times.
[0261] The results show that:
[0262] SD rats were injected intravenously / muscularly with 1.0 mg / kg Pegloticase and pegylated uricase injection multiple times. No abnormal changes related to drugs were observed in the general condition of the rats.
[0263] 4.3.1 Anti-PEG antibody detection
[0264] After 4 consecutive administrations of SD rats, no anti-PEG antibodies and anti-PHC antibodies were detected in all individual animals before the first administration; after the administration, no anti-PHC antibodies were detected in all animals, and anti-PEG antibodies were detected in the intravenous and intramuscular injection groups of Pegloticase, and the intravenous and intramuscular injection groups of PEGylated uricase injection, with the positive results ratios of 3 / 8, 1 / 8, 1 / 8, and 1 / 8, respectively. PEG immunohistochemistry showed that weak positive expression of PEG was observed in the spleen, liver, and kidney of the intravenous and intramuscular injection groups of pegloticase. No positive expression of PEG was observed in the intravenous and intramuscular injection groups of PEGylated uricase injection. The results are shown in Table 16.
[0265] From the above analysis, it can be seen that the antibodies generated by PU5 and pegloticase are mainly antibodies against the PEG part, rather than antibodies against the urate oxidase part.
[0266] The results of PEG antibodies and PEG immunohistochemistry showed that the intramuscular administration group was superior to the intravenous administration group in terms of PU5 and pegloticase. Among them, the anti-PEG antibodies produced by the intravenous administration group were superior to pegloticase in PU5; and the anti-PEG antibodies produced by the intramuscular administration group were superior to pegloticase.
[0267] Table 16: PEG immunohistochemistry positive expression results
[0268]
[0269] Positive grading: 1 = weak positive, 2 = weak positive, 3 = moderately positive, 4 = strong positive.
[0270] 4.3.2 Pharmacokinetic testing
[0271] After multiple intravenous and intramuscular injections of Pegloticase and Pegylated Uricase Injection in SD rats, there was no significant gender difference in the main pharmacokinetic parameters of each group of animals. After four consecutive administrations, the two drugs accumulated slightly in the rats.
[0272] SD rats were given the same dose (1.0 mg / kg) of the marketed drug Pegloticase by multiple intravenous / muscular injections. After the first dose, the absolute bioavailability in the rats was 51.35%; after the last dose, the absolute bioavailability in the rats was 45.98%. SD rats were given the same dose (1.0 mg / kg) of pegylated uricase injection by multiple intravenous / muscular injections. After the first dose, the absolute bioavailability in the rats was 58.29%; after the last dose, the absolute bioavailability in the rats was 52.60%.
[0273] 4.3.3 Comparison of in vivo efficacy (uric acid)
[0274] SD rats were injected intravenously and intramuscularly with 1.0 mg / kg Pegloticase and pegloticase injection for 4 times (once a week). The serum uric acid concentration was maintained at a low level after each administration. Pegloticase intramuscular injection showed recovery 14 days after the last administration, and the other groups showed recovery 18 days after the last administration. Compared with the same dose of the marketed drug Pegloticase, the maintenance time of the intravenous injection group of the two drugs was relatively consistent, while the maintenance time of the intramuscular injection group of pegloticase injection was longer than that of the marketed drug, that is, the efficacy of PU5 in intramuscular administration is better than that of Pegloticase.
[0275] The above results are shown in Tables 17 to 20. Figures 14 to 19 shown.
[0276] Table 17: Average pharmacokinetic parameters of SD rats after continuous intravenous injection of Pegloticase and pegylated uricase injection
[0277]
[0278]
[0279] Table 18: Mean pharmacokinetic parameters of SD rats after continuous intramuscular injection of Pegloticase and pegylated uricase injection
[0280]
[0281]
[0282] Table 19: Uric acid statistical results of each dose group after multiple intramuscular / intravenous injections of Pegloticase and pegylated uricase injection in SD rats (Mean±SD)
[0283]
[0284]
[0285] In the description of this specification, the description with reference to the terms "one embodiment", "some embodiments", "example", "specific example", or "some examples" etc. means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic representations of the above terms do not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described may be combined in any one or more embodiments or examples in a suitable manner. In addition, those skilled in the art may combine and combine the different embodiments or examples described in this specification and the features of the different embodiments or examples, without contradiction. SEQUENCE LISTING <110> Chongqing Paijin Biotechnology Co., Ltd. <120> Method for preparing polyethylene glycol-modified uricase <130> PIDC3191171 <160> 7 <170> PatentIn version 3.3 <210> 1 <211> 298 <212> PRT <213> artificial <220> <223> 1 <400> 1 Thr Tyr Lys Lys Asn Asp Glu Val Glu Phe Val Arg Thr Gly Tyr Gly 1 5 10 15 Lys Asp Met Ile Lys Val Leu His Ile Gln Arg Asp Gly Lys Tyr His 20 25 30 Ser Ile Lys Glu Val Ala Thr Thr Val Gln Leu Thr Leu Ser Ser Lys 35 40 45 Lys Asp Tyr Leu His Gly Asp Asn Ser Asp Val Ile Pro Thr Asp Thr 50 55 60 Ile Lys Asn Thr Val Asn Val Leu Ala Lys Phe Lys Gly Ile Lys Ser 65 70 75 80 Ile Glu Thr Phe Ala Val Thr Ile Cys Glu His Phe Leu Ser Ser Phe 85 90 95 Lys His Val Ile Arg Ala Gln Val Tyr Val Glu Glu Val Pro Trp Lys 100 105 110 Arg Phe Glu Lys Asn Gly Val Lys His Val His Ala Phe Ile Tyr Thr 115 120 125 Pro Thr Gly Thr His Phe Cys Glu Val Glu Gln Ile Arg Asn Gly Pro 130 135 140 Pro Val Ile His Ser Gly Ile Lys Asp Leu Lys Val Leu Lys Thr Thr 145 150 155 160 Gln Ser Gly Phe Glu Gly Phe Ile Lys Asp Gln Phe Thr Thr Leu Pro 165 170 175 Glu Val Lys Asp Arg Cys Phe Ala Thr Gln Val Tyr Cys Lys Trp Arg 180 185 190 Tyr His Gln Gly Arg Asp Val Asp Phe Glu Ala Thr Trp Asp Thr Val 195 200 205 Arg Ser Ile Val Leu Gln Lys Phe Ala Gly Pro Tyr Asp Lys Gly Glu 210 215 220 Tyr Ser Pro Ser Val Gln Lys Thr Leu Tyr Asp Ile Gln Val Leu Thr 225 230 235 240 Leu Gly Gln Val Pro Glu Ile Glu Asp Met Glu Ile Ser Leu Pro Asn 245 250 255 Ile His Tyr Leu Asn Ile Asp Met Ser Lys Met Gly Leu Ile Asn Lys 260 265 270 Glu Glu Val Leu Leu Pro Leu Asp Asn Pro Tyr Gly Lys Ile Thr Gly 275 280 285 Thr Val Lys Arg Lys Leu Ser Ser Arg Leu 290 295 <210> 2 <211> 304 <212> PRT <213> artificial <220> <223> 2 <400> 2 Met Ala His Tyr Arg Asn Asp Tyr Lys Lys Asn Asp Glu Val Glu Phe 1 5 10 15 Val Arg Thr Gly Tyr Gly Lys Asp Met Ile Lys Val Leu His Ile Gln 20 25 30 Arg Asp Gly Lys Tyr His Ser Ile Lys Glu Val Ala Thr Ser Val Gln 35 40 45 Leu Thr Leu Ser Ser Lys Lys Asp Tyr Leu His Gly Asp Asn Ser Asp 50 55 60 Val Ile Pro Thr Asp Thr Ile Lys Asn Thr Val Asn Val Leu Ala Lys 65 70 75 80 Phe Lys Gly Ile Lys Ser Ile Glu Thr Phe Ala Val Thr Ile Cys Glu 85 90 95 His Phe Leu Ser Ser Phe Lys His Val Ile Arg Ala Gln Val Tyr Val 100 105 110 Glu Glu Val Pro Trp Lys Arg Phe Glu Lys Asn Gly Val Lys His Val 115 120 125 His Ala Phe Ile Tyr Thr Pro Thr Gly Thr His Phe Cys Glu Val Glu 130 135 140 Gln Ile Arg Asn Gly Pro Pro Val Ile His Ser Gly Ile Lys Asp Leu 145 150 155 160 Lys Val Leu Lys Thr Thr Gln Ser Gly Phe Glu Gly Phe Ile Lys Asp 165 170 175 Gln Phe Thr Thr Leu Pro Glu Val Lys Asp Arg Cys Phe Ala Thr Gln 180 185 190 Val Tyr Cys Lys Trp Arg Tyr His Gln Gly Arg Asp Val Asp Phe Glu 195 200 205 Ala Thr Trp Asp Thr Val Arg Ser Ile Val Leu Gln Lys Phe Ala Gly 210 215 220 Pro Tyr Asp Lys Gly Glu Tyr Ser Pro Ser Val Gln Lys Thr Leu Tyr 225 230 235 240 Asp Ile Gln Val Leu Thr Leu Gly Gln Val Pro Glu Ile Glu Asp Met 245 250 255 Glu Ile Ser Leu Pro Asn Ile His Tyr Leu Asn Ile Asp Met Ser Lys 260 265 270 Met Gly Leu Ile Asn Lys Glu Glu Val Leu Leu Pro Leu Asp Asn Pro 275 280 285 Tyr Gly Arg Ile Thr Gly Thr Val Lys Arg Lys Leu Thr Ser Arg Leu 290 295 300 <210> 3 <211> 297 <212> PRT <213> artificial <220> <223> 3 <400> 3 Met Tyr Lys Asn Asp Glu Val Glu Phe Val Arg Thr Gly Tyr Gly Lys 1 5 10 15 Asp Met Val Lys Val Leu His Ile Gln Arg Asp Gly Lys Tyr His Ser 20 25 30 Ile Lys Glu Val Ala Thr Ser Val Gln Leu Thr Leu Ser Ser Lys Lys 35 40 45 Asp Tyr Val Tyr Gly Asp Asn Ser Asp Ile Ile Pro Thr Asp Thr Ile 50 55 60 Lys Asn Thr Val His Val Leu Ala Lys Phe Lys Gly Ile Lys Ser Ile 65 70 75 80 Glu Thr Phe Ala Met Asn Ile Cys Glu His Phe Leu Ser Ser Phe Asn 85 90 95 His Val Ile Arg Ala Gln Val Tyr Val Glu Glu Val Pro Trp Lys Arg 100 105 110 Phe Glu Lys Asn Gly Val Lys His Val His Ala Phe Ile His Asn Pro 115 120 125 Thr Gly Thr His Phe Cys Glu Val Glu Gln Met Arg Ser Gly Pro Pro 130 135 140 Val Ile His Ser Gly Ile Lys Asp Leu Lys Val Leu Lys Thr Thr Gln 145 150 155 160 Ser Gly Phe Glu Gly Phe Ile Lys Asp Gln Phe Thr Thr Leu Pro Glu 165 170 175 Val Lys Asp Arg Cys Phe Ala Thr Lys Val Tyr Cys Lys Trp Arg Tyr 180 185 190 His Gln Gly Arg Asp Val Asp Phe Glu Ala Thr Trp Asp Thr Val Arg 195 200 205 Asp Ile Val Leu Glu Lys Phe Ala Gly Pro Tyr Asp Lys Gly Glu Tyr 210 215 220 Ser Pro Ser Val Gln Lys Thr Leu Tyr Asp Ile Gln Val His Ser Leu 225 230 235 240 Ser Arg Val Pro Glu Met Glu Asp Met Glu Ile Ser Leu Pro Asn Ile 245 250 255 His Tyr Phe Asn Ile Asp Met Ser Lys Met Gly Leu Ile Asn Lys Glu 260 265 270 Glu Val Leu Leu Pro Leu Asp Asn Pro Tyr Gly Lys Ile Thr Gly Thr 275 280 285 Val Lys Arg Lys Leu Ser Ser Arg Leu 290 295 <210> 4 <211> 304 <212> PRT <213> artificial <220> <223> 4 <400> 4 Met Ala His Tyr His Asn Asp Tyr Lys Lys Asn Asp Glu Val Glu Phe 1 5 10 15 Val Arg Thr Gly Tyr Gly Lys Asp Met Val Lys Val Leu His Ile Gln 20 25 30 Arg Asp Gly Lys Tyr His Ser Ile Lys Glu Val Ala Thr Ser Val Gln 35 40 45 Leu Thr Leu Ser Ser Lys Lys Asp Tyr Val Tyr Gly Asp Asn Ser Asp 50 55 60 Ile Ile Pro Thr Asp Thr Ile Lys Asn Thr Val His Val Leu Ala Lys 65 70 75 80 Phe Lys Gly Ile Lys Ser Ile Glu Thr Phe Ala Met Asn Ile Cys Glu 85 90 95 His Phe Leu Ser Ser Phe Asn His Val Ile Arg Ala Gln Val Tyr Val 100 105 110 Glu Glu Val Pro Trp Lys Arg Phe Glu Lys Asn Gly Val Lys His Val 115 120 125 His Ala Phe Ile His Asn Pro Thr Gly Thr His Phe Cys Glu Val Glu 130 135 140 Gln Met Arg Ser Gly Pro Pro Val Ile His Ser Gly Ile Lys Asp Leu 145 150 155 160 Lys Val Leu Lys Thr Thr Gln Ser Gly Phe Glu Gly Phe Ile Lys Asp 165 170 175 Gln Phe Thr Thr Leu Pro Glu Val Lys Asp Arg Cys Phe Ala Thr Lys 180 185 190 Val Tyr Cys Lys Trp Arg Tyr His Gln Gly Arg Asp Val Asp Phe Glu 195 200 205 Ala Thr Trp Asp Thr Val Arg Asp Ile Val Leu Glu Lys Phe Ala Gly 210 215 220 Pro Tyr Asp Lys Gly Glu Tyr Ser Pro Ser Val Gln Lys Thr Leu Tyr 225 230 235 240 Asp Ile Gln Val His Ser Leu Ser Arg Val Pro Glu Met Glu Asp Met 245 250 255 Glu Ile Ser Leu Pro Asn Ile His Tyr Phe Asn Ile Asp Met Ser Lys 260 265 270 Met Gly Leu Ile Asn Lys Glu Glu Val Leu Leu Pro Leu Asp Asn Pro 275 280 285 Tyr Gly Arg Ile Thr Gly Thr Ala Lys Arg Lys Leu Ala Ser Lys Leu 290 295 300 <210> 5 <211> 304 <212> PRT <213> artificial <220> <223> 5 <400> 5 Met Ala His Tyr His Asn Asp Tyr Gln Lys Asn Asp Glu Val Glu Phe 1 5 10 15 Val Arg Thr Gly Tyr Gly Lys Asp Met Val Lys Val Leu His Ile Gln 20 25 30 Arg Asp Gly Lys Tyr His Ser Ile Lys Glu Val Ala Thr Ser Val Gln 35 40 45 Leu Thr Leu Asn Ser Arg Arg Glu Tyr Leu His Gly Asp Asn Ser Asp 50 55 60 Ile Ile Pro Thr Asp Thr Ile Lys Asn Thr Val Gln Val Leu Ala Lys 65 70 75 80 Phe Lys Gly Ile Lys Ser Ile Glu Thr Phe Ala Met Asn Ile Cys Glu 85 90 95 His Phe Leu Ser Ser Phe Asn His Val Ile Arg Val Gln Val Tyr Val 100 105 110 Glu Glu Val Pro Trp Lys Arg Phe Glu Lys Asn Gly Val Lys His Val 115 120 125 His Ala Phe Ile His Thr Pro Thr Gly Thr His Phe Cys Glu Val Glu 130 135 140 Gln Leu Arg Ser Gly Pro Pro Val Ile His Ser Gly Ile Lys Asp Leu 145 150 155 160 Lys Val Leu Lys Thr Thr Gln Ser Gly Phe Glu Gly Phe Leu Lys Asp 165 170 175 Gln Phe Thr Thr Leu Pro Glu Val Lys Asp Arg Cys Phe Ala Thr Gln 180 185 190 Val Tyr Cys Lys Trp Arg Tyr His Gln Gly Arg Asp Val Asp Phe Glu 195 200 205 Ala Thr Trp Glu Ala Val Arg Gly Ile Val Leu Lys Lys Phe Ala Gly 210 215 220 Pro Tyr Asp Lys Gly Glu Tyr Ser Pro Ser Val Gln Lys Thr Leu Tyr 225 230 235 240 Asp Ile Gln Val Leu Ser Leu Ser Gln Leu Pro Glu Ile Glu Asp Met 245 250 255 Glu Ile Ser Leu Pro Asn Ile His Tyr Phe Asn Ile Asp Met Ser Lys 260 265 270 Met Gly Leu Ile Asn Lys Glu Glu Val Leu Leu Pro Leu Asp Asn Pro 275 280 285 Tyr Gly Arg Ile Thr Gly Thr Val Lys Arg Lys Leu Thr Ser Arg Leu 290 295 300 <210> 6 <211> 304 <212> PRT <213> artificial <220> <223> 6 <400> 6 Met Ala His Tyr His Asn Asp Tyr Lys Lys Asn Asp Glu Val Glu Phe 1 5 10 15 Val Arg Thr Gly Tyr Gly Lys Asp Met Val Lys Val Leu His Ile Gln 20 25 30 Arg Asp Gly Lys Tyr His Ser Ile Lys Glu Val Ala Thr Ser Val Gln 35 40 45 Leu Thr Leu Ser Ser Lys Lys Asp Tyr Leu His Gly Asp Asn Ser Asp 50 55 60 Ile Ile Pro Thr Asp Thr Ile Lys Asn Thr Val His Ala Leu Ala Lys 65 70 75 80 Phe Lys Gly Ile Lys Ser Ile Glu Ala Phe Ala Val Asn Ile Cys Gln 85 90 95 His Phe Leu Ser Ser Phe Asn His Val Ile Arg Thr Gln Val Tyr Val 100 105 110 Glu Glu Ile Pro Trp Lys Arg Leu Glu Lys Asn Gly Val Lys His Val 115 120 125 His Ala Phe Ile His Thr Pro Thr Gly Thr His Phe Cys Glu Val Glu 130 135 140 Gln Leu Arg Ser Gly Pro Pro Val Ile His Ser Gly Ile Lys Asp Leu 145 150 155 160 Lys Val Leu Lys Thr Thr Gln Ser Gly Phe Glu Gly Phe Ile Lys Asp 165 170 175 Gln Phe Thr Thr Leu Pro Glu Val Lys Asp Arg Cys Phe Ala Ala Gln 180 185 190 Val Tyr Cys Lys Trp Arg Tyr His Gln Cys Arg Asp Val Asp Phe Glu 195 200 205 Ala Thr Trp Asp Thr Ile Arg Asp Val Val Leu Glu Lys Phe Ala Gly 210 215 220 Pro Tyr Asp Lys Gly Glu Tyr Ser Pro Ser Val Gln Lys Thr Leu Tyr 225 230 235 240 Asp Ile Gln Val Val Ser Leu Ser Gln Val Pro Glu Ile Asp Asp Met 245 250 255 Glu Ile Ser Leu Pro Asn Ile His Tyr Phe Asn Ile Asp Met Ser Lys 260 265 270 Met Gly Leu Ile Asn Lys Glu Glu Val Leu Leu Pro Leu Asp Asn Pro 275 280 285 Tyr Gly Lys Ile Thr Gly Thr Val Lys Arg Lys Leu Ser Ser Arg Leu 290 295 300 <210> 7 <211> 304 <212> PRT <213> artificial <220> <223> 7 <400> 7 Met Ala Asp Tyr His Asn Asn Tyr Lys Lys Asn Asp Glu Leu Glu Phe 1 5 10 15 Val Arg Thr Gly Tyr Gly Lys Asp Met Val Lys Val Leu His Ile Gln 20 25 30 Arg Asp Gly Lys Tyr His Ser Ile Lys Glu Val Ala Thr Ser Val Gln 35 40 45 Leu Thr Leu Ser Ser Lys Lys Asp Tyr Leu His Gly Asp Asn Ser Asp 50 55 60 Ile Ile Pro Thr Asp Thr Ile Lys Asn Thr Val His Val Leu Ala Lys 65 70 75 80 Phe Lys Gly Ile Lys Ser Ile Glu Ala Phe Gly Val Asn Ile Cys Glu 85 90 95 Tyr Phe Leu Ser Ser Phe Asn His Val Ile Arg Ala Gln Val Tyr Val 100 105 110 Glu Glu Ile Pro Trp Lys Arg Leu Glu Lys Asn Gly Val Lys His Val 115 120 125 His Ala Phe Ile His Thr Pro Thr Gly Thr His Phe Cys Glu Val Glu 130 135 140 Gln Leu Arg Ser Gly Pro Pro Val Ile His Ser Gly Ile Lys Asp Leu 145 150 155 160 Lys Val Leu Lys Thr Thr Gln Ser Gly Phe Glu Gly Phe Ile Lys Asp 165 170 175 Gln Phe Thr Thr Leu Pro Glu Val Lys Asp Arg Cys Phe Ala Thr Gln 180 185 190 Val Tyr Cys Lys Trp Arg Tyr His Gln Cys Arg Asp Val Asp Phe Glu 195 200 205 Ala Thr Trp Gly Thr Ile Arg Asp Leu Val Leu Glu Lys Phe Ala Gly 210 215 220 Pro Tyr Asp Lys Gly Glu Tyr Ser Pro Ser Val Gln Lys Thr Leu Tyr 225 230 235 240 Asp Ile Gln Val Leu Ser Leu Ser Arg Val Pro Glu Ile Glu Asp Met 245 250 255 Glu Ile Ser Leu Pro Asn Ile His Tyr Phe Asn Ile Asp Met Ser Lys 260 265 270 Met Gly Leu Ile Asn Lys Glu Glu Val Leu Leu Pro Leu Asp Asn Pro 275 280 285 Tyr Gly Lys Ile Thr Gly Thr Val Lys Arg Lys Leu Ser Ser Arg Leu 290 295 300
Claims
1. A method for preparing polyethylene glycol-modified uricase, characterized in that: include: Conducting a coupling reaction between uricase and polyethylene glycol to obtain polyethylene glycol-modified uricase; Wherein, the polyethylene glycol is provided in the form of an acidic solution, the concentration of hydrogen ions in the acidic solution is 1-5 mmol / L, and the concentration of the polyethylene glycol in the acidic solution is 100-300 mmol / L; The molecular weight of the polyethylene glycol is 0.5~20 KD; The polyethylene glycol has a monomethoxy group or a hydroxyl group; The polyethylene glycol is a modified polyethylene glycol, and the modification group of the modified polyethylene glycol is selected from at least one of the following: N-hydroxysuccinimide, N-hydroxysuccinimide carbonate, N-hydroxysuccinimide acetate, N-hydroxysuccinimide propionate, N-hydroxysuccinimide butyrate, N-hydroxysuccinimide succinate, and p-nitrophenyl carbonate; The urate oxidase has an amino acid sequence shown in any one of SEQ ID NOs: 1 to 7; The molar ratio of uricase to polyethylene glycol is 1:(56-94).
2. The method according to claim 1, characterized in that The acidic solution is an acidic solution containing an organic acid or an inorganic acid; The organic acid is selected from: Acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid, malonic acid, adipic acid, ascorbic acid, benzenesulfonic acid, benzoic acid, butyric acid, cyclopentylpropionic acid, digluconic acid, dodecylsulfuric acid, ethanesulfonic acid, formic acid, fumaric acid, glucoheptonic acid, glycerophosphoric acid, gluconic acid, heptanoic acid, hexanoic acid, 2-hydroxy-ethanesulfonic acid, lactobionic acid, lactic acid, lauric acid, laurylsulfuric acid, malic acid, methanesulfonic acid, 2-naphthalenesulfonic acid, nicotinic acid, oleic acid, palmitic acid, pectic acid, 3-phenylpropionate, picrate, pivalic acid, propionic acid, stearic acid, p-toluenesulfonic acid, undecanoic acid, valeric acid; The inorganic acid is selected from: Hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, perchloric acid, hydroiodic acid, nitric acid, persulfuric acid, boric acid, dichromic acid, silicic acid, chromic acid, thiocyanic acid.
3. The method according to claim 2, characterized in that The acidic solution contains hydrochloric acid or sulfuric acid or glacial acetic acid.
4. The method according to claim 1, characterized in that: The polyethylene glycol is a straight chain or branched chain structure.
5. The method according to claim 1, characterized in that: The polyethylene glycol is coupled to uricase via an amide bond.
6. The method according to claim 1, characterized in that The modified group of the modified polyethylene glycol is N-hydroxysuccinimide propionate.
7. The method according to claim 1, characterized in that The coupling reaction is carried out in a carbonate buffer solution.
8. The method according to claim 7, characterized in that The pH of the carbonate buffer solution is 9-11.
9. The method according to claim 1, characterized in that: The concentration of the urate oxidase in the coupling reaction system is 10 mg / ml.
10. The method according to claim 1, characterized in that The coupling reaction is carried out at 5-30° C. for at least 60 minutes.
11. The method according to claim 1, characterized in that: At least 11 of the following amino acid sites in the uricase are PEG-modified, T 1 , K 3 , K 4 , K 30 , K 35 , K 76 , K 79 , K 97 , K 112 , K 116 , K 120 , K 152 , K 179 , K 222 , K 231 , K 266 , K 272 , K 285 , K 291 , K 293 ; The amino acid site positioning is based on the amino acid sequence shown in SEQ ID NO:
1.
12. The method according to claim 1, characterized in that The uricase has an amino acid sequence shown in any one of SEQ ID NOs: 1 to 4.
13. The method according to any one of claims 1 to 12, characterized in that: The polyethylene glycol-modified uricase has a PEG modification at at least one of the following four amino acid sites: K 30 , K 35 , K 222 and K 231 ; The amino acid site positioning is based on the amino acid sequence shown in SEQ ID NO:
1.
14. The method according to any one of claims 1 to 12, characterized in that: Compared with the peptide map of the uricase not modified by polyethylene glycol, the peptide map of the uricase modified by polyethylene glycol has a relative ratio of peak area reduction of at least 11 predetermined peptide segments that is not less than 80%.
15. The method according to any one of claims 1 to 12, characterized in that: Compared with the peptide map of the uricase not modified by polyethylene glycol, the peptide map of the uricase modified by polyethylene glycol has a relative ratio of peak area reduction of at least 11 predetermined peptide segments that is not less than 90%.
16. A method for reducing the immunogenicity of urate oxidase, characterized in that: At least 11 of the following amino acid sites of the polyethylene glycol-modified uricase are PEG-modified, T 1 , K 3 , K 4 , K 30 , K 35 , K 76 , K 79 , K 97 , K 112 , K 116 , K 120 , K 152 , K 179 , K 222 , K 231 , K 266 , K 272 , K 285 , K 291 , K 293 The amino acid site positioning is based on the amino acid sequence shown in SEQ ID NO: 1, and the method comprises: Conducting a coupling reaction between urate oxidase and polyethylene glycol; Wherein, the polyethylene glycol is provided in the form of an acidic solution, the concentration of hydrogen ions in the acidic solution is 1-5 mmol / L, and the concentration of the polyethylene glycol in the acidic solution is 100-300 mmol / L; The molecular weight of the polyethylene glycol is 0.5~20 KD; The polyethylene glycol has a monomethoxy group or a hydroxyl group; The polyethylene glycol is a modified polyethylene glycol, and the modification group of the modified polyethylene glycol is selected from at least one of the following: N-hydroxysuccinimide, N-hydroxysuccinimide carbonate, N-hydroxysuccinimide acetate, N-hydroxysuccinimide propionate, N-hydroxysuccinimide butyrate, N-hydroxysuccinimide succinate, and p-nitrophenyl carbonate; The urate oxidase has an amino acid sequence shown in any one of SEQ ID NOs: 1 to 7; The molar ratio of uricase to polyethylene glycol is 1:(56-94).
17. The method according to claim 16, characterized in that The acidic solution contains an organic acid or an inorganic acid, The organic acid comprises at least one selected from the following: Acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid, malonic acid, adipic acid, ascorbic acid, benzenesulfonic acid, benzoic acid, butyric acid, cyclopentylpropionic acid, digluconic acid, dodecylsulfuric acid, ethanesulfonic acid, formic acid, fumaric acid, glucoheptonic acid, glycerophosphoric acid, gluconic acid, heptanoic acid, hexanoic acid, 2-hydroxy-ethanesulfonic acid, lactobionic acid, lactic acid, lauric acid, laurylsulfuric acid, malic acid, methanesulfonic acid, 2-naphthalenesulfonic acid, nicotinic acid, oleic acid, palmitic acid, pectic acid, 3-phenylpropionate, picrate, pivalic acid, propionic acid, stearic acid, p-toluenesulfonic acid, undecanoic acid, valeric acid; The inorganic acid comprises at least one selected from the following: Hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, perchloric acid, hydroiodic acid, nitric acid, persulfuric acid, boric acid, dichromic acid, silicic acid, chromic acid, thiocyanic acid.
18. The method according to claim 16, characterized in that The acidic solution contains hydrochloric acid or sulfuric acid or glacial acetic acid.
19. The method according to claim 16, characterized in that The coupling reaction is carried out in a carbonate buffer solution.
20. The method according to claim 19, characterized in that The pH of the carbonate buffer solution is 9-11.
21. The method according to claim 16, characterized in that The concentration of the urate oxidase in the coupling reaction system is 10 mg / ml.
22. The method according to claim 16, characterized in that The coupling reaction is carried out at 5-30° C. for at least 60 minutes.
